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Summary  
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with motor 
deteriorations in the world. Clinical manifestation includes symptoms like movement 
deficiencies, tremor, rigidity, bradykinesia, postural instability, and also dementia. PD is 
characterized by a vast loss of dopaminergic neurons in the substantia nigra pars compacta and 
the morphological hallmark of Lewy bodies and Lewy neurits, protein deposits within brain 
neurons. Alpha-synuclein (aSYN), a major constituent of these inclusions is localized at 
presynaptic sites in brain neurons and plays physiologically distinct roles in the modulations of 
synaptic activity, neurotransmitter release and lipid metabolism. It is still not fully understood 
which trigger initiates the deposition of aSYN in the brain of patients with PD and other 
neurodegenerative diseases. Mitochondrial dysfunction accompanied by the production of 
reactive oxygen species is currently debated to cause the pathological alterations in the brain of 
PD patients. 
In the present work, a transgenic aSYN mouse model with the human ‘A30P’ mutation (tg-aSYN) 
was characterized and compared to a newly generated transgenic mouse model with specific 
mitochondrial polymorphisms, the tg-aSYN-mtNOD mice. In order to examine the influence of 
mitochondrial function modification, biochemical and histological aspects as well as the 
behavioural profiles were determined and compared in both mouse models. Respirometric 
measurements of isolated mouse brain mitochondria were conducted in order to evaluate 
functional effects of these mitochondrial polymorphisms and to find differences in complex-
dependent respiration when compared to the conventional tg-aSYN mouse model. The results 
reveal that these specific mitochondrial polymorphisms lead to an increased complex II-
dependent respiration that is accompanied by an improvement of motor performances and 
cortical neuron number in old tg-aSYN-mtNOD mice. An increase in higher-molecular weight 
species of aSYN was furthermore found as well as an enhanced microglial response in the brain. 
Based on the premise of a negatively affected energy metabolism in tg-aSYN mice, an additional 
study was performed to investigate a hypothesized export of aSYN by the energy-dependent 
ABC transporter ABCC1. Therefore, an ABCC1 knock-out mouse model was generated and 
investigated with regard to intracerebral aSYN level and neuronal and microglial cortex area. 
Furthermore, tg-aSYN mice were treated with thiethylperazine to assess the effects of ABCC1 
activation on the stated parameter. It was thereby found that aSYN is not transported by ABCC1 
as no significant differences upon knock-out as well as activation were determined in tg-aSYN 
mice. In summary, this study was able to reveal beneficial effects of increased complex 
II-dependent respiration on the aSYN pathology in a PD mouse model and points to promising 
pharmaceutical application option for the treatment of α-synucleinopathies. 
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Abbreviations 
% percent  
° degree 
°C degree Celsius 
α-KG alpha-ketoglutarate 
A30P alanine to proline change at 
amino acid 30 in α-synuclein 
transcript 
A53T alanine to threoine change at 
amino acid 53 in α-synuclein 
transcript 
Aβ Amyloid β 
ABC ATP-binding cassette 
AD Alzheimer’s disease 
ADP adenosine diphosphate 
AGC mitochondrial 
aspartate/glutamate carrier 
ASAT aspartate amino-transaminase 
Aqua dest. aqua destillata 
aralar mitochondrial 
aspartate/glutamate carrier 
aSYN alpha synuclein 
ATP adenosine triphosphate 
ATP13A2 Probable cation-transporting 
ATPase 13A2 
Atr atractyloside 
BBB blood brain barrier 
BCB blood cerebrospinal fluid barrier 
BIM brain incubation medium 
BLP basolateral amygdaloid nucleus, 
posterior part 
BMP basomedial amygdaloid nucleus, 
posterior part 
bp base pairs 
BSA bovine serum albumin 
CA cornu ammonis 
COX cytochrome c oxidase 
cp cerebral peduncle 
CSF cerebrospinal fluid 
CSPα cysteine string protein α 
Ctrl control 
d days 
DG dentate gyrus 
DLB Dementia with Lewy bodies 
DLG dorsal lateral geniculate nucleus 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
E46K glutamic acid to lysine change at 
amino acid 46 in α-synuclein 
transcript 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ELISA Enzyme-linked immunosorbent 
assay 
ETC electron transport chain 
ETF electron-transferring 
flavoprotein-ubichinone 
oxidoreductase 
FAD flavin adenine dinucleotide 
FMN+ flavin mononucleotide 
fr fasciculus retroflexus 
G3P gylerine-3-phosphate 
GABA gamma-aminobutyric acid 
GFAP glial fibrillary acid protein 
Glu glutamate 
GWAS genome-wide association study 
Hc hippocampus 
HD Huntington’s disease 
HIF hypoxia-inducible transcriptions 
factor 
HRP horseradish peroxidase 
HT hypothalamus 
Iba1 ionized calcium binding adapter 
molecule 1 
IL-6 Interleukin-6 
kDa kilodalton 
kPa kilopascal 
LB Lewy body 
lmec linear mixed-effects models with 
censored responses 
LN Lewy neurit 
LRP-1 low density lipoprotein 
receptor-related protein 1 
LRRK2 leucine-rich repeat kinase 2 
LV lateral ventricle 
M molar 
Mal malate 
MAS malate/aspartate shuttle 
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MDR1 multidrug resistance protein 1 
MOPS 3-(N-orpholino) propane- 
sulfonic acid 
MPP+ 1-methyl-4-phenylpyridinium 
ion 
MPT medial pretectal nucleus 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetra- 
hydropyridine 
MRP1 multidrug resistance-associated 
protein 1 
MSA multiple system atrophy 
MSE buffer containing mannitol-
sucrose-EGTA 
mtDNA mitochondrial DNA 
n number 
NAC non-Amyloid β component 
NAD+ nicotinamide adenine 
dinucleotide 
ND Neurodegenerative disease 
NeuN anti-neuronal nuclei 
nm nanometer 
nmol nanomole 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PD Parkinson’s disease 
PDGF platelet-derived growth factor 
PFA paraformaldehyde 
P-gp P-glycoprotein 1 
PINK1 PTEN (Phosphatase and tensin 
homolog )-induced putative 
kinase 1 
PMCo posteromedial cortical 
amygdaloid area 
PTP permeability transition pore 
Pyr pyruvate 
RCR respiratory control ratio 
REML restricted maximum likelihood 
RNA ribonucleic acid 
rpm rounds per minute 
RSD retrosplenial dysgranular cortex 
SC somatosensory cortex 
SDH succinate dehydrogenase 
SEM standard error of mean 
SN Substantia nigra 
SNAP-25 synaptosomal-associated 
protein 25 
 
SNARE soluble NSF (N-ethylmaleimide-
sensitive factor) attachment 
protein receptor 
SNCA alpha synuclein-gene 
SNP single nucleotide polymorphism 
SNpc Substaintia nigra pars compacta 
SUCC succinate 
T thalamus 
TAE tris-acetate-EDTA 
Taq Thermus aquaticus 
Tg transgenic 
Thy1 thymocyte differentiation 
antigen 1 
TMB 3,3',5,5'-tetramethylbenzidine 
TMPD N,N,N′,N′-tetramethyl-p-
phenylenediamine 
TNFα tumor necrosis factor α 
tRNA transfer ribonucleic acid 
UPS ubiquitin proteasome system 
VD Vascular dementia 
w/v weight/volume 
ZID zona incerta, dorsal part 
  
units according to SI 
  
Introduction 
9 
 
1. Introduction 
1.1  Neurodegenerative Diseases 
Neurodegeneration describes a pathological process in the brain of elderly which leads to a 
progressing loss of neurons in specific brain structures and consequently to a gradual worsening 
of several related functions until death occurs (Przedborski et al., 2003). Neurodegenerative 
diseases (NDs) cover a large group of devastating neurological diseases with different 
manifestations and clinical outcome like dementia, atrophy and movement deterioration 
(Przedborski et al., 2003). They are categorized according to the location of the neuronal 
dysfunction in the brain and/or their ability to trigger dementia. But commonly a definite 
diagnosis can only be made post mortem (Massano et al., 2012). The most prominent NDs 
include Alzheimer’s disease (AD), Parkinson’s disease (PD) and vascular dementia (VD) but also 
multiple system atrophy (MSA), Huntington’s disease (HD) and prion diseases belong to this 
group (Przedborski et al., 2003). They all share as common hallmark the main risk factor age. As 
the human population grows older, especially in the Western society, incidence of NDs increases 
rapidly. Prognoses further underline the importance of research in this field (World Alzheimer 
Report 2010; World Population Prospects: The 2012 Revision, Key Findings and Advance Tables). 
Besides having an inherited defect (<1 %) and old age, only presumptions exist concerning the 
cause of the diseases. It is likely that most NDs are initiated multifactorial. Here, stroke, 
infection, trauma, diabetes as well as depression, alcohol abuse and/or high blood pressure are 
discussed and even social and environmental factors like low education, ethnicity and/or 
exposition to pesticides were taken into consideration (Landrigan et al., 2005; Baltazar et al., 
2014; Olanow et al., 1999). A widely discussed cause for NDs is mitochondrial dysfunction and 
the resulting production of reactive oxygen species (ROS) in cells which leads to damage and 
malfunction (Martin, 2010). A further characteristic of certain NDs is the excessive production 
and intra- or extracellular deposition of different peptides and proteins e.g. Amyloid β in AD or 
α-synuclein in PD causing dementia and other clinical manifestations. The reason for the 
disturbed balance in those systems is still unknown and thus a wide spread subject of research 
(Swart et al., 2014).  
1.2  Dementia 
Dementia describes a clinical syndrome which can be caused by injuries or follows diseases of 
the brain (e.g. NDs) and leads to abnormal cognitive function in elderly. Although also younger 
people can suffer from this disease, the risk to develop dementia is highest from the age of 65 
years and almost doubles every five years (World Alzheimer Report 2009). It affects several 
cognitive abilities like memory, orientation and learning, emotional and social behavior and also 
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motivation, each case proceeding individually. To diagnose dementia, apart from memory at 
least one other function has to be affected, for example motoric activity, speech development or 
object recognition. Furthermore, for diagnosis, cognitive decline is required to be not reversible 
by medication (The ICD-10 Classification of Mental and Behavioural Disorders). Most cases are 
caused directly by disturbed mechanisms in the brain and are denoted as primary dementia 
whereas few cases occur secondarily as a consequence of metabolic disease or wrong 
medication (Mahler et al., 1987). Different stages underline the progressive nature of dementia. 
First, cases usually present with mild symptoms like confusion, spatial or temporal 
disorientation. In the second stage patients forget their familiar surroundings and develop 
problems with speech and communication. In the last stage of dementia, complete care is 
necessary as patients have problems in walking, handling and in coordination of time and place. 
They are not able to recognize close relatives and often become aggressive and apathetic (2008 
Alzheimer's disease facts and figures). Further important symptoms which appear with 
dementia include depression, hallucination and often anxiety (Mahler et al., 1987; de Araujo et 
al., 2014). Strengthening the rising importance of dementia, the latest Manual of Mental 
Disorders (DSM-5) constitutes a new entity in which dementia and amnestic disorders together 
form the group of ‘major neurocognitive disorder (NCD)’ (Diagnostic and Statistical Manual of 
Mental Disorders, 2013). More than half of the world wide dementia cases are classified as AD 
(World Alzheimer Report 2009). In Germany dementia is located among the ten most occurring 
causes of death along with heart diseases, stroke and lung illnesses (statistisches Bundesamt, 
2014). High numbers of incidence, 7.7 million new patients every year (Dementia, 2012) and 
high economic cost, £23 billion (€ 28.5 billion) per year as pointed out by the Alzheimer’s 
Research Trust in the United Kingdom (Luengo-Fernandez, 2010) show the urgent demand for 
research on this field and especially new therapy options. 
1.3 Parkinson’s Disease  
1.3.1 Definition & Epidemiology 
Parkinson’s disease (PD) is a common form of neurodegenerative diseases and is thought to 
affect approximately 1.8 % of all people aged 65 years or older (Mollenhauer, 2010). 
Furthermore, it is the prevalent ‘synucleinopathy’, which describes an array of progressing 
degenerative diseases that share the abnormal deposition of α-synuclein in form of inclusion 
bodies. Other diseases belonging to this group are for example MSA, Dementia with Lewy 
Bodies, Lewy Body variant of Alzheimer’s disease and neurodegeneration with brain iron 
accumulation type 1 (Del Tredici, 2000).  
PD was first described in 1817 by James Parkinson in his monograph “Assay on the Shaking 
Palsy” and was renamed after his first descriptor by Jean-Martin Charcot more than 50 years 
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later (Goetz, 2011). The disease is clinically characterized by cardinal symptoms leading to 
‘parkinsonism’, a syndrome which can be found in any patient with striatal damage or striatal 
dopamine deficiency, although PD is by far the most common cause. Those symptoms include 
tremor at rest, rigidity, bradykinesia and postural instability, making PD the most common 
movement disorder (Dickson et al., 2009b). The progressing character of PD leads to a 
worsening of symptoms until daily life is no longer to cope with. A variety of further symptoms 
occurs during disease development, including hypokinesia, akinesia, hypomimia, hypophonia 
and problems with swallowing and writing. The general passive and apathetic behavior is 
reinforced by an accompanying depression and dementia (Dauer et al., 2003). These two non-
motor manifestations indicate that PD is a multisystemic disorder of the central nervous system 
(Massano et al., 2012). 
1.3.2 Pathophysiology 
Pathological findings in the brain reveal a tremendous loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc), which is located in the mesencephalon (midbrain). The 
cell bodies of the dopaminergic neurons are located within the SNpc, whilst the axons project 
into the striatum, which consists of putamen and caudate. Here, mainly neurons innervating the 
putamen are affected by a marked loss; they are projected from the primary sensory and motor 
cortices. Those cells innervating the caudate, which receives inputs from frontal and parietal 
association areas, display only moderate damage (Dauer et al., 2003). This nigrostriatal pathway 
is part of the basal ganglia circuitry, which is involved in movement control and production and 
allows the correct execution of voluntary motion (Obeso et al., 2008). As a consequence of the 
neuronal loss in the SNpc the concentration of the neurotransmitter dopamine and its 
metabolites decrease markedly in the striatum. This concentration imbalance triggers a whole 
cascade of events in the basal ganglia circuitry. The subsequently decreased activation of 
GABAergic neurons in the striatum leads to a diminished inhibition of the glutamatergic neurons 
in the Nucleus subthalamicus as well as the GABAergic neurons of Substantia nigra pars 
reticulate and globus pallidus pars interna. As a consequence an increased neuronal activity in 
these both output nuclei results in excessive inhibition of the ventrolateral thalamus which is 
connected to cortical and subcortical motor areas (Figure 1) (Blandini et al., 2000). 
Introduction 
12 
 
 
Figure 1: Nigrostriatal pathology in the PD brain.  
A displays a schematic illustration of the basal ganglia circuitry ("Physiologie" 4. Edition 2004). B shows the difference 
in the nigrostriatal pathway between a normal and a PD brain (Dauer et al., 2003).  
The loss of neurons is greatest in the lateral ventral part of the SNpc (Fearnley et al., 1991), 
where the death of neuromelanin containing cells leads to the characteristic pathological finding 
of depigmentation in this area (see Figure 1B). Interestingly, as it could be shown that the loss of 
neuron terminals in the striatum is more prominent than the loss of the dopaminergic neuron 
cell bodies in the SNpc, the idea of the “dying back” hypothesis emerged (Bernheimer et al., 
1973). This assumption starts from the premise that the main target of the degenerative process 
might be the neuron terminals rather than cell bodies as found in studies with MPTP (1-methyl-
4-phenyl-1,2,3,6-tetra-hydropyridine)-treated mice which lack neuron loss in the SNpc if the 
axons and terminals in the striatum were protected (Wu et al., 2003). The striatal cell loss is 
accompanied by an inflammatory reaction produced by activated microglia, as it was found in 
the SNpc of PD patients. The increased production of cytokines leads to neuron damage in these 
areas which can be prevented by early application of anti-inflammatory drugs (Schiess, 2003). 
However, the role of microglia is discussed controversially for their part in neurodegenerative 
diseases (Russo et al., 2014; Tansey et al., 2010). 
In addition to the dopaminergic cell loss also other neurotransmitter systems can be involved. 
Histological analyzes revealed neurodegeneration also in the serotonergic, noradrenergic and 
cholinergic system and in corresponding anatomical structures like locus coeruleus, nucleus 
basalis or raphe (Espay et al., 2014). 
The progress of PD can be subdivided into stages according to involved areas and the 
corresponding degree of degradation. Interestingly, in the first and second stage of the disease 
the SNpc remains normal and does not show any abnormality. In this time patients often 
complain about an impaired sense of smelling, sometimes years before the first motor 
symptoms emerge. Consistent with this finding, the first lesions occur in the anterior olfactory 
nucleus as well as in the olfactory bulb. After that, deteriorations in the lower brain stem appear 
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where the gain setting nuclei are located. In stage three and four the impairment of SNpc follows 
and in later stage five and six also thalamus and neocortical areas are included in the 
degenerative process. At this stages important structures of the limbic system display damages 
especially amygdala and hippocampus leading do cognitive deficits and dementia (for details see 
Table 1) (Braak et al., 2003). 
Table 1: Stages and affected brain structures in PD pathology 
(adopted from (Braak et al., 2003)) 
Stage Affected brain structures 
I Medulla oblongata, dorsal IX/X motor nucelus, intermediate reticular zone 
II Caudal raphe nuclei, gigantocellular reticular nucleus, coeruleus-subcoeruleus complex 
III Midbrain, especially SNpc 
IV 
Prosencephalic lesions, temporal mesocortex (transentorhinal region), allocortex (CA2-
plexus) 
V High order sensory association areas of neocortex and prefrontal neocortex 
VI 
First order sensory association areas of neocortex and premotor areas, mild changes in 
primary sensory areas and primary motor field possible 
 
The diagnosis of PD is not only based on dopaminergic cell loss but requires also the presence of 
another pathological hallmark in the brain, Lewy bodies (LBs) and Lewy neurites (LNs) 
(Massano et al., 2012). LBs are cytoplasmic protein aggregates, which are located in the cell 
soma of specific neurons. They comprise of α-synuclein (aSYN), ubiquitin, synphilin, parkin, and 
neurofilaments and build a nearly insoluble aggregate. LBs are not unique to PD but can be 
found in other synucleinopathies, too. They show a highly organized structure with a dense 
hyaline core and a surrounding halo and have a diameter of approximately 15 µm (Dickson et al., 
2009b). Within the cell they occupy most of the cell body and inevitably lead to its death. The 
most affected anatomical structure is first of all the SNpc but in severe cases also amygdala and 
cortex bear LBs (Braak et al., 2003). According to current research, the deposition of LBs is 
causative for the massive loss of dopaminergic neurons in the SNpc. LNs are probably pre-stage 
to LBs as they come in a thread-like shape and are mostly located in axons where they impair the 
metabolism of the cell (Dickson et al., 2009a). As aSYN is the major constituent of these 
formations, much attention in the field of research has been devoted to this protein. It will be 
further described in an own section (see 1.4). 
1.3.3 Genetics & Etiology 
Idiopathic PD, which accounts for 90 % of all cases worldwide, occurs due to unknown 
mechanisms and develops sporadically on the basis of old age. In contrast, familial PD emerges 
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from genetic predisposition i.e. mutations in specific genes. These rare cases (< 10 %) provide 
the basis for most of the research done today. Until now 28 specific chromosomal loci have been 
linked to PD. Even though some loci still lack confirmation, six have been identified in which 
mutations directly lead to monogenic PD in either autosomal-dominant or autosomal-recessive 
manner (Klein et al., 2012; Bertram et al., 2005). 
Among them, mutations in SNCA (PARK1/PARK4, synuclein, alpha [non A4 component of 
amyloid precursor]) lead to early-onset PD developing at an age of 50 years or earlier. The 
disease progresses rapidly with a severe phenotype and dementia as a usual syndrome (Bonifati, 
2014). This rare locus hosts only three known mutations as well as duplication and triplication 
of the coding region. The mutations were found in few families worldwide. The most prominent 
is A53T (Alanine to Threonine in exon 4) followed by A30P (Alanine to Proline in exon 3) and 
E46K (glutamic acid to lysine in exon 3) which were each present in only one family so far 
(Zarranz et al., 2004; Kruger et al., 1998; Singleton et al., 2013). A possible mechanism through 
which mutations in this gene cause PD is thought to be a gain of toxicity due to shift in 
conformation of α-synuclein to form stable β-sheets known to be more prone to aggregation (for 
further details see 1.4.2) (Brucale et al., 2009). 
Beside those genes leading to monogenic forms of PD (SNCA, LRRK2, Parkin, PINK1, DJ-1 and 
ATP13A2) there are some further loci which are considered to be at least causative for PD. As 
mentioned before, some of the loci are not certain or lack confirmation or they are linked to PD 
but the gene remains to be identified, other lead to parkinsonism as part of some different 
disease. But based on GWAS (genome-wide association study) and other studies, it was possible 
to not only identify additional genes (e.g. MAPT, NAT2, GAK) but also length- and SNP (single 
nucleotide polymorphism) variants in SNCA and LRRK2 leading to monogenic PD (Klein et al., 
2012). 
However, genetic predisposition is not the only known risk factor beside age. Etiological factors 
in PD include also bacterial and viral infections, plant derived toxins, polluted water, industrial 
chemicals and other rural and environmental influences (Priyadarshi et al., 2001). Here 
especially insecticides and herbicides as environmental toxins play an important role. Most 
importantly, MPTP, a byproduct of the synthesis of a heroine-like drug, caused a stir among 
researchers as it was found to induce irreversible parkinsonism in humans of all ages and thus, 
was the first identified dopaminergic neurotoxin, confirmed by using rhesus monkeys (Langston 
et al., 1983; Burns et al., 1983). Interestingly, its derivate MPP+ (1-methyl-4-phenylpyridinium 
ion), which is produced in astrocytes via monooxidase type B, was shown to inhibit complex I of 
the mitochondrial electron transport chain in dopaminergic neurons (Nicklas et al., 1985; Singer 
et al., 1987). Several other similar substances have been found, for example Paraquat, a 
herbicide which is structurally similar to MPTP or rotenone, a plant derived household 
insecticide which functions like MPTP as a mitochondrial poison (Betarbet et al., 2000; Maturana 
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et al., 2014). As a consequence of disturbed mitochondrial function oxidative stress emerges in 
the form of ROS and may lead to cell death. Consequently, inhibition can prevent MPTP-induced 
parkinsonism (Przedborski et al., 1992; Przedborski et al., 1996). Mitochondrial dysfunction as 
cause of PD is a well-accepted hypothesis among researchers and is therefore further described 
in section 1.5. Altogether, these findings gave interesting insights into the mechanisms leading to 
PD. However, a causative role of those toxins for idiopathic PD seems unlikely as MPTP induced 
parkinsonism is not progressive and does not lead to Lewy body pathology or other pathologies 
in the brain (Schapira et al., 2011; Jenner, 2003). 
1.3.4 Therapy 
Until today there is no cure for PD. Thus, symptomatic therapy is applied, since 1969 most 
commonly by administration of L-dopa, the precursor for the biosynthesis of various 
neurotransmitters such as dopamine. As a consequence, the dopamine level increases in the 
remaining dopaminergic neurons in the SNpc and striatum, compensating the loss of neurons in 
these areas and leading to a reduction of various symptoms (Cotzias et al., 1969). Similar results 
are achieved by enzyme replacement therapy, in which genes encoding important enzyme for 
biosynthesis of dopamine become transferred into neurons of the striatum. Gene therapy, a 
novel method, provides genetic modifications of cells via viral or non-viral methods and leads 
also to an improvement of disease symptoms and to a decrease of side effects. An increase or 
reduction in gene expression can be achieved depending on the functional impairment 
(Bjorklund et al., 2010; Coune et al., 2012). The providing of the tyrosine hydroxylase gene, an 
enzyme in the biosynthesis of L-dopa, leads to a long term production of the enzyme and 
consequently dopamine (Kaplitt et al., 1994). Another well-examined factor essential for therapy 
in PD is the growth factor GDNF (glial cell line-derived neurotrophic factor). It was shown that 
GDNF enhances the survival of dopaminergic neurons and increases axonal sprouting 
(Rosenblad et al., 1998; Connor et al., 2001). Promising results were gathered using a lentiviral 
vector delivering GDNF into specific areas of the brain. In a non-human primate model of PD it 
was possible to inhibit degeneration of cells and improve motoric function (Kordower et al., 
2000).  
Moreover, deep brain stimulation is currently a well examined method to provide regaining of 
dopamine signaling via stimulation of the subthalamic nucleus. It furthermore leads to a 
reduction of drug intake and side effects (Benabid et al., 2009).  
However, the benefits of increasing the availability of dopamine are limited, since the chronic 
intake of L-dopa leads to severe side effects such as dyskinesia and dosage has to be increased 
regularly (Coune et al., 2012). But even the successful gene therapy may only give benefits for a 
certain time frame or might only treat some symptoms. It was found that often even if motor 
deficits or other symptoms may be improved by therapy, the quality of life improves not. 
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Patients often suffer from social isolation and communication problems (Mylene et al., 2013). To 
find best therapy options and a possible cure it is necessary to understand the metabolic basics 
that underlie the pathophysiology of PD and to prevent onset of the disease at the stage when 
neurons are still alive. 
1.4  Alpha-synuclein 
1.4.1 Characteristics & Function 
Alpha synuclein (αSYN) is a 140 amino acid protein, which was assumed to be located to 
presynaptic sites in neurons of the brain and was therefore denoted synuclein (Iwai et al., 1995). 
The first description was made based on isolated αSYN from the electrical organ of Torpedo 
californica (Maroteaux et al., 1988). Today it is considered to be homolog to the human γ-
synuclein (Maroteaux et al., 1991). Besides α- and γ-synuclein, the family of synucleins includes 
also β-synuclein, which all share the same amino-terminal sequence but differ in the carboxy-
terminal part (Tofaris et al., 2005). Human αSYN is a protein of about 14 kDa and was first 
isolated due to its NAC fragment (non-Amyloid β component), which was found to be involved in 
Amyloid β pathogenesis in Alzheimer’s disease (Ma et al., 2003). It represents 1 % of all cytosolic 
proteins in the brain (Iwai et al., 1995). Structurally, the protein can be divided into the N-
terminal, the central- and the C-terminal region (see Figure 2). In the N-terminal part (amino 
acid 1-60) the three familial PD mutations can be found as well as amino acid repeats with the 
conserved KTKEGV motif. Furthermore, it hosts apolipoprotein lipid-biding motifs which 
support the forming of α-helical structures when binding to membranes. The central region 
(amino acid 61-95) is hydrophobic and comprises the NAC fragment, which is highly prone to 
aggregation. The last part (amino acid 96-140) is the C-terminal region. It contains many proline 
residues, which disrupt the secondary structure and make this part unstructured (Bellucci et al., 
2012). 
 
Figure 2: α- synuclein transcript with mutations respectively phosphorylation and nitration sites  
(Bellucci et al., 2012). 
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αSYN is defined as a ‘natively unfolded’ protein as it does not form a secondary structure in 
aqueous solutions (Weinreb et al., 1996). However, Bartels et al. (2011) found a folded tetramer 
of 58 kDa when using non-denaturing condition for the isolation from various different cell lines. 
They propose that destabilization of this tetramer leads to the abnormal aggregation potential of 
αSYN in PD. On the other hand, this topic was discussed controversially by Burre et al. (2013), 
who found αSYN as an unstructured monomer. Even if unstructured, preferences to obtain 
α-helices were observed, mainly in the N-terminal region of αSYN when binding to lipids, 
whereas the formation of fibrils is accompanied by β-sheet structures. The aggregation rate of 
αSYN furthermore can be promoted by factors such as low pH, the presence of Cu2+ or mutations 
(McClendon et al., 2009; Montes et al., 2014). 
Three different splicing variant of αSYN in humans could be identified so far, including aSYN 
126, aSYN 112 and aSYN 98 with different functional properties. While aSYN 126 was found to 
have protective effects in the aging brain, the other splicing variants promote aggregation of 
aSYN (Beyer et al., 2009). 
The function of αSYN is still not fully known. Very early, increased expression of the protein was 
found in a specific neuron population during the process of song learning in songbirds and thus, 
was hypothesized to relate to synaptic plasticity (Bellucci et al., 2012). Today it is thought that 
the protein is implicated in the maintenance of synaptic membranes as well as the control of the 
expression, distribution and activity of specific proteins in the synapse. Furthermore, 
neurotransmitter release might be regulated by αSYN via control of synaptic activity. It was 
found that αSYN knock-out mice display an increased dopamine release, indicating a regulative 
function of the protein in the synapse (Abeliovich et al., 2000). αSYN may also facilitate the 
neurotransmitter release by increasing the formation of SNARE (soluble NSF attachment protein 
receptor) complexes, as it binds to synaptobrevin-2 (VAMP2, vesicle associated membrane 
protein 2) (Burre et al., 2010). Even if contradictory results exist with respect to its implication 
in neurotransmitter release, there are promising results indicating an important role for αSYN in 
this metabolism (Cabin et al., 2002; Chandra et al., 2004). A connection between aSYN and 
SNARE complexes was found in 2005. Chandra et al. were able to show that the deletion of CSPα 
(cysteine string protein α) in mice leads to a severe neurodegeneration phenotype (Chandra et 
al., 2005). CSPα is known to serve as a chaperone in a complex together with other proteins and 
is able for example to refold denatured luciferase (Tobaben et al., 2001) respectively prevents 
the aggregation of SNAP-25 (synaptosomal-associated protein 25), an important protein of the 
SNARE complex. The deletion of CSPα inhibits a proper SNARE complex assembly and increases 
ubiquitination and degradation of SNAP-25. Interestingly, an overexpression of αSYN was able 
to rescue the SNARE complex formation and the loss of SNAP-25, thus preventing 
neurodegeneration (Chandra et al., 2005). The findings were confirmed by Burre et al. (2010), 
who found a linear relationship between SNARE complex assembly and αSYN level. Consistent 
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with that, αSYN is situated in equilibrium of free and membrane- respectively vesicle-bound 
states (Bisaglia et al., 2006). 
Additionally, the association of αSYN with the negatively charged membrane led to the 
assumption that it plays a role in modulating membrane lipids and its organization (Madine et 
al., 2006; Kamp et al., 2006) and is therefore involved in the cerebral lipid homeostasis (Kim et 
al., 2012). It was furthermore observed that the mass of cerebral cholesterol, cholesteryl esters 
and triacylgylcerols increased upon a deletion of aSYN in mice (Barcelo-Coblijn et al., 2007). The 
binding of aSYN to lipids enabled the protein to form α-helical structures and to fibrillate (Lee et 
al., 2003; Zhu et al., 2003). 
These recent results, discussed in various reviews (Stefanis, 2012; Bellucci et al., 2012; Lee et al., 
2006), give only little insight into what is known of αSYN and its function today. Thus even if the 
exact role of αSYN remains still not fully understood, certain interesting mechanisms through 
which αSYN may function in the cell were already described. 
1.4.2 Genetics 
As mentioned before (1.3.3), missense mutations in the gene encoding αSYN (SNCA), as well as 
duplication or triplication, have been found to cause rare forms of familial PD. Depending on the 
mutation, the clinical and pathological manifestation can be completely different. The most 
common mutations are A53T, A30P and E46K which all lead to altered aggregation of αSYN 
(Lazaro et al., 2014; Li et al., 2001). 
The interaction of αSYN with negatively charged liposomes is increased with the E46K mutated 
protein leading to an enhanced filament assembly (Choi et al., 2004). However, it displays less 
fibril formation in vitro compared to wildtype protein (Fredenburg et al., 2007). In contrast to 
that, the A53T mutation more rapidly leads to fibril formation in vitro than A30P mutated or 
wildtype αSYN (Conway et al., 2000). Whereas A30P mutated αSYN shows a less abundant 
interaction with lipids of vesicles and membranes (Jo et al., 2002; Stockl et al., 2008), the 
formation of fibrils was slower compared to wildtype, especially at low concentrations (Li et al., 
2001), but oligomerization was faster in comparison (Krasnoslobodtsev et al., 2013). However, a 
reduced formation of inclusions was confirmed when compared to E46K mutated aSYN (Lazaro 
et al., 2014). The A30P (and A53T) mutation reduces the hydrophobicity of the protein (Li et al., 
2001). The interactions of the N-terminus are altered with these mutations and lead to 
interactions with the C-terminal end (Krasnoslobodtsev et al., 2013). Additionally, the tendency 
to form α-helices in the N-terminal region was lower whereas it was enhanced in the case of β-
sheets, possibly leading to altered aggregation as observed by Fourier transform infrared 
spectroscopy and Small angle X-ray scattering measurements (Li et al., 2001; Li et al., 2002). 
Interestingly, even though the α-helical structure formation was decreased due to the A30P 
mutation, no changes in β-sheet organization could be found in the αSYN protein structure 
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performing annealing molecular dynamics simulations (Balesh, 2011). Remarkably, Burre et al. 
(2012) have recently shown that the A30P mutation is unique among the αSYN mutations, as it 
solely leads to decreased synaptic targeting and diminished SNARE complex stability in vitro, 
proposing that the alanine may be crucial for α-helix formation. 
Even though these mutations and the resulting PD cases are rare, they are highly important for 
the understanding of the pathophysiology of PD and, thus, for the research in this field, as they 
enable the modeling of the sporadic disease. 
1.4.3  Pathology & Toxicity 
The deposition of αSYN inside neurons leads to degeneration of those and to the symptoms 
occurring in several disease of the synucleopathy group. Beside genetic mutations, which 
account for only less than 10 % of all cases, posttranslational modifications have been in focus of 
research. Several interesting observations have been made concerning alterations occurring in 
wildtype aSYN (Bellucci et al., 2012). 
The main reason for aSYN to gain toxicity is thought to be the building of insoluble aggregates. 
Natively unfolded aSYN monomers start to form β-sheet rich oligomers, the protofibrils. These 
further form specific structures leading to more stable amyloid-like fibrils, which aggregate as 
Lewy bodies (Moore et al., 2005). 
Several posttranslational modifications are known today to alter the biophysical properties of 
the protein. The most prominent is the phosphorylation of serine at position 129 by casein 
kinase 1 and 2 (Okochi et al., 2000) or G-protein-coupled kinases (Pronin et al., 2000). As a 
consequence of the modification at the C-terminal site, fibrillation is promoted (Fujiwara et al., 
2002). Especially different modifications at the C-terminal part were found to alter the 
propensity of aSYN to aggregate, underlined by the finding that C-terminally truncated aSYN 
tends to form pathological accumulations in vivo and in vitro (Ulusoy et al., 2010; Tofaris et al., 
2006). 
Tyrosine nitration is another posttranslational modification known to occur in aSYN, leading to 
increased fibril formation. The nitration of tyrosine at position 39 located in the N-terminal part 
was found not only to promote aggregation but also to prevent the binding of aSYN to lipid 
vesicles, hence interfering with its physiological function. Furthermore, nitration slows down 
the process of proteasomal degradation (Giasson et al., 2000; Hodara et al., 2004). 
Even the binding to lipids contains some difficulties, as the exposure to polyunsaturated fatty 
acids was shown to cause multimer/oligomer formation in vitro and in vivo (Perrin et al., 2001; 
Sharon et al., 2003). However, this topic is discussed controversially due to conflicting findings 
(Schapira et al., 1990; Trostchansky et al., 2006). 
Recently, the role of protein degradation and clearance mechanisms in the pathogenesis of 
neurodegenerative diseases gained increasing attention. As the correlation between protein 
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deposition and magnitude of disease failed until now, the hypothesis emerged that soluble 
monomeric respectively oligomeric peptides are toxic species and aggregated protein is, in fact, 
a protective mechanism (Kopito, 2000; Pahnke et al., 2009). 
As the cell dynamically synthesizes and degrades proteins in order to ensure equilibrium, a 
defective degradation system would likely lead to tremendous impacts on the cell physiology. 
One degradation mechanism to dispose misfolded or damaged proteins is the ubiquitin 
proteasome system (UPS), which degrades proteins that are covalently bound to ubiquitin. Parts 
of the UPS as well as ubiquitinated proteins have been found in LBs, suggesting an impairment of 
the UPS in the pathophysiology of PD, which might be potentiated by the further accumulation of 
aSYN (Schlossmacher et al., 2002; Emmanouilidou et al., 2010). The finding that nearly all aSYN 
aggregated in LBs is phosphorylated at Serine-129 further supported the theory, because it was 
previously reported that Serine-129-phophorylated aSYN can directly be degraded by the UPS 
without former ubiquitination (Machiya et al., 2010). Interestingly, it could also be revealed that 
an exposure to environmental toxins such as rotenone and MPTP (as described before in 1.3.3) 
led to an impairment of the UPS in vitro and in vivo (Zeng et al., 2006; Wang et al., 2006). 
Furthermore, the finding of a very early onset variant of PD caused by parkin mutations, a gene 
coding E3 ubiquitin ligase, and the notion that no LB formation can be found in those cases 
underlined the concept of protein deposition being a protective mechanism of the cell to 
attenuate the toxicity of soluble protein. 
Another way of degradation implicated in PD includes the lysosomes via micro- and 
macroautophagy. Using macroautophagy the cell is able to degrade a complete component of the 
cytosol including aggregated protein depositions, which may lead to failure in case of overload. 
Furthermore, the sequestered proteins might become a “source of reactive oxygen species 
inside” (Cook et al., 2012). 
It has long been thought that aSYN, as intracellular protein, cannot be found in the cerebrospinal 
fluid (CSF). However, convincing counterevidence was brought by Borghi et al. (2000); El-Agnaf 
et al. (2003), who proved the presence of aSYN in the CSF and plasma of PD patients as well as 
healthy controls. One possible explanation pointed out by the authors is the aSYN efflux from the 
brain since it was similarly discovered for Aß in a mouse model of AD. Here, the transport via 
ABC transporter was found to be involved (Kortekaas et al., 2005; Krohn et al., 2011). 
1.4.4 ABC transporter & PD 
In recent years, a special transport system came into focus of neurodegeneration research, the 
ABC transporter (ATP-binding cassette transporter). Until today, 49 human ABC transporters 
were described subdivided into seven families (A to G) and distributed in different tissues, e.g. 
liver, lung, and blood-brain-barrier (BBB) as well as choroid plexus (reveiewed in (Pahnke et al., 
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2014). This large group of integral membrane proteins uses the energy of ATP to facilitate the 
influx of nutrients into the brain and the efflux of toxic compounds from the brain via the 
BBB/blood-cerebrospinal fluid (CSF)-barrier (BCB) by an active transport mechanism (Miller, 
2015). Their localization in the membrane of epithelial cells of the BBB respectively the BCB 
enables them to be a functional barrier to protect against hazardous substances from the blood 
stream/CSF (Begley, 2004). 
It was successfully proved that ABC transporters are crucial in the prevention and treatment of 
several diseases, particularly multidrug resistance in cancer and recently the proteopathies in 
the brain (Pahnke et al., 2013). Especially in mouse models of Alzheimer’s disease (AD) 
(Vogelgesang et al., 2004; Cirrito et al., 2005; Lam et al., 2001), but also in PD patients (Bartels et 
al., 2008b; Bartels et al., 2009), several studies could show the contribution of ABC transporters, 
especially ABCB1 (P-glycoprotein, P-gp), on the clearance of toxic peptides from the brain 
(Kortekaas et al., 2005). Even though, a diminished ABCB1 function was never confirmed in 
early stages of PD, it was in healthy elderly controls, therefore it probably doesn’t play a 
causative role in PD pathogenesis (Bartels et al., 2008a). 
ABCA5 is an ABC transporter known to transport mainly lipids, e.g. sphingomyelin, and was 
recently found to be elevated in the brains of PD patients (Kim et al., 2012) and associated with a 
reduced risk for developing PD revealed by GWAS (Simon-Sanchez et al., 2009). 
Interestingly, another ABC transporter of this family was reported to be implicated in the 
transport of aSYN, ABCA8. In the context of MSA, ABCA8 expression was reported to be 
upregulated with a concomitantly increased expression of aSYN in the affected regions of the 
brain (Bleasel et al., 2013). 
Only just, the ABCC1 transporter (Multidrug resistance-associated protein 1, MRP1) revealed 
promising results by reducing the Aβ burden in the diseased brain of an AD-mouse model upon 
pharmacologically increased activity and further supported the comprehension of the 
importance of this system. Interestingly, the knock-out of ABCC1 and the following decrease of 
the export function of only 11 % led to a 4-fold increased Aβ load (Krohn et al., 2011). However, 
the possible impact of ABCC1 on the pathogenesis of PD was never studied so far and its further 
investigation is of utmost interest. 
1.5  Mitochondria 
1.5.1 Structure & Function 
Mitochondria are 1-4 µm sized cell organelles, which can be found in any eukaryotic cell except 
for erythrocytes (Kennady et al., 2004; Cimen, 2008). Due to their main function of producing 
adenosine triphosphate (ATP) via oxidative phosphorylation, they are also denoted as 
“powerhouse of the cell” (Perier et al., 2012). 
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Several cellular functions like muscle contractions, generation of ion gradients and synthesis of 
molecules highly depend on supply of ATP provided by mitochondria. Beside ATP production 
also other pathways are located within the matrix for example hem biosynthesis and urea cycle. 
Furthermore, Ca2+ homeostasis and apoptosis are both facilitated by opening of the permeability 
transition pore (PTP), either reversibly or irreversibly. By uncoupling of the oxidative 
phosphorylation mitochondria can also produce heat (Leonard et al., 2000; Bonda et al., 2010). 
Their characteristic structure, comprising of outer and inner membrane, the inter membrane 
space and the matrix, is adjusted to their physiological role. The outer membrane is permeable 
for small molecules (< 6 kDa) which can enter via porines (Zalman et al., 1980; Gellerich et al., 
2000) and voltage dependent anion channels (Blachly-Dyson et al., 1993), but otherwise 
displays a concentration gradient (Gellerich et al., 1994). Additionally, larger molecules can 
enter using translocases of the outer membrane. The inner membrane builds several 
convolutions looming into the matrix (cristae), leading to an enhanced membrane surface 
necessary to provide the needed energy supply. Here, the complexes of the electron transport 
chain are situated as well as the PTP. The inner membrane itself is impermeable, especially for 
ions, thus metabolites can only pass via specific transport molecules (Bohnert et al., 2012; 
Mannella, 2006). The matrix within the inner membrane contains RNA- and DNA polymerases, 
tRNAs and the mitochondrial genome (mtDNA) as well as several enzymes which are necessary 
for the citrate cycle, oxidation of pyruvate and fatty acids, and other biochemical processes 
(Alberts B., 2002). 
The human mitochondrial genome is a double stranded circular plasmid containing 37 genes 
which code only for part of the mitochondrial proteins, while the rest is imported from the 
cytosol of the cell. Only 13 of these genes are necessary for complexes of the respiratory chain. 
Every mitochondrion hosts 2 to 10 copies of its own DNA. In contrast to the nuclear genome the 
mitochondrial genome is inherited only maternally via mitochondria in the ovum. Thus, gene 
defects and related diseases can only be passed on by the mother (Schon et al., 2012). 
1.5.2  The electron transport chain 
The most prominent function of mitochondria is the production of energy in form of ATP 
(adenosine triphosphate) by oxidative phosphorylation. This is ensured by using the energy of 
the reduction of oxygen to water to produce ATP from ADP (adenosine diphosphate). The 
reaction is realized in steps which take place in the complexes of the electron transport chain 
(ETC, respiratory chain). 
Briefly, preceding this process is the glycolysis in which glucose is degraded to pyruvate in the 
cytosol of the cell; this step includes the production of NADH from NAD+ (nicotinamide adenine 
dinucleotide). Pyruvate is transported into the mitochondrial matrix where it is converted into 
acetyl-CoA via oxidative decarboxylation, which becomes further oxidized during the citrate 
Introduction 
23 
 
cycle. Additionally, the citrate cycle leads to the production of NADH and FADH from NAD+ 
respectively FAD (flavin adenine dinucleotide) which are used to transfer electrons that 
emerged during the cycle to the complexes of the ETC (see Figure 3) ("Biochemie: Eine 
Einführung für Mediziner und Naturwissenschaftler" 2004). 
 
Figure 3: Schematic illustration of the ETC and additionally reactions catalyzed by complex I and II  
(Cuperus et al., 2010). 
The ETC comprises of four complexes (I–IV) and the ATP-synthase. Complex I (NADH-
dehydrogenase-ubiquinone oxidoreductase) starts transferring two electrons from NADH from 
the citrate cycle to FMN+ (flavin mononucleotide) under the production of FMNH2 and NAD+. 
NADH which is made during glycolysis is transported into the matrix via glycerol-3-phosphate 
shuttle using glycerol-3-phosphate, which oxidizes to dihydroxyacetone phosphate, and to 
deliver two electrons and protons to FAD. The shuttle requires Ca2+ for activation (McKenna et 
al., 2006). Those two electrons, shifted to FMN by NADH, are further transferred to ubiquinone 
via iron-sulfur clusters. Subsequently, four protons are transported from the matrix into the 
inter membrane space. Complex II (Succinate dehydrogenase-ubiquinone oxidoreductase, SDH) 
is not involved in the transport of protons across the membrane but also donates electrons to 
reduce ubiquinone (coenzyme Q). This reduction is achieved through the dehydration of 
succinate to fumarate and the adjoining reduction of FAD to FADH. The reduced ubiquinone 
passes its electrons to cytochrome c via complex III (ubiquinone-cytochrome c oxidoreductase) 
and is thereby oxidized again, while cytochrome c becomes reduced. Meanwhile, four protons 
are transported across the membrane. In complex IV (cytochrome c oxidase), the oxidization of 
cytochrome affiliates and O2 is reduced to H2O, leading to proton crossing through the 
membrane once more. The so-built proton gradient is simultaneously used by the ATP-synthase 
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(ATPase) to generate ATP from ADP and phosphate. The ADP/ATP translocase then transfers 
ATP into the matrix in exchange of ADP (Cecchini, 2003).  
As the oxygen consumption is tightly coupled to the ATP production, it is possible to divide the 
respiration into different functional states, as done by Chance et al. in 1955 (see Table 2). In this 
classification, state 4 displays a resting state, in which no ADP is phosphorylated due to 
insufficient supply, following no ATP is produced and respiration proportionately low, unless 
the inner membrane is uncoupled respectively damaged. State 3 refers to the maximal possible 
respiration reached when the cell is sufficiently supplied with substrate, oxygen and ADP and 
the limitation is only given by the enzymatic reaction of the single complexes of the ETC (Chance 
et al., 1955). 
Table 2: Classification of functional states of mitochondrial respiration  
(adopted from (Chance et al., 1955)) 
state ADP level substrate level Limiting substance  
1 low low ADP 
2 high ~0 Substrate 
3 high high respiratory chain 
4 low high ADP 
5 high high oxygen [<0] 
 
1.5.3 Mitochondrial alterations & PD 
The link between mitochondrial alterations and neurodegenerative diseases has been made on 
the basis of several indicators that were found to be involved in one or several diseases, such as 
structural alterations, diminished ATP production, increased ROS, mutations in the 
mitochondrial genome, deficiency in complexes of the ETC as well as impairments in 
mitochondrial motility and Ca2+ homeostasis (Perier et al., 2012). 
The association of mitochondrial dysfunction with the pathogenesis of PD has been in focus of 
research since it was observed, that complex I-deficiency due to exposure to MPTP, first 
unintentionally by drug addicts and later experimentally in nonhuman primates and mice, leads 
to dopaminergic neuron loss in the SNpc and the development of parkinsonism (Dauer et al., 
2003). The identification of further complex I inhibitors like rotenone and other pesticides 
confirmed these findings (Betarbet et al., 2000; Hong et al., 2014; Richardson et al., 2009). 
Complex I deficiency was also discovered in brains of patients with sporadic PD (Schapira et al., 
1990) and could be bypassed in mice by probably increasing an complex II-depending 
mechanism (Tieu et al., 2003) or by using an alternative electron carrier (methylene blue) in rats 
(Wen et al., 2008). 
One of the consequences of a reduced complex I activity is an unsufficient supply with ATP as it 
was found in the brain of mice (Dias et al., 2013). However, a depletion of complex I activity as 
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severe as needed to cause a reduced ATP level couldn’t be found in PD patients and is therefore 
not likely to cause sporadic PD (Perier et al., 2012), it might still support disease progression. 
Inherited PD can be initiated by mutations in the mitochondrial genome (mtDNA). For example, 
mutations in the mtDNA polymerase γ lead to parkinsonism (Luoma et al., 2004). However, 
mutations in the mtDNA are thought to occur during life with increasing age as part of normal 
aging (Lin et al., 2006). By creating a mouse model with mutated, proof-reading deficient mtDNA 
polymerase, Trifunovic et al. were able to show that mutations in the mtDNA led to decreased 
life span of mice according to an early onset of various ageing-related phenotypes (Trifunovic et 
al., 2004). Further evidence for the link between mitochondria alteration and PD was recently 
presented by Rhinn et al., who describe a shift in the preferred accumulation site of aSYN from 
synaptic terminals towards mitochondria initiated by a specific transcript variant of αSYN, 
referred to as αSynL (Rhinn et al., 2012). 
One of the most discussed incidences, in connection with mitochondrial alterations, is the 
increased production of reactive oxygen species (ROS). ROS emerges endogenously during 
oxidative phosphorylation when molecular oxygen is reduced to superoxide anion (
⋅) instead 
of converted into water in the mitochondria. This happens when the oxidative phosphorylation 
is inhibited or excessive calorie consumption took place. Normally, ROS is neutralized by 
antioxidants, such as glutathione and carotenoids, as well as enzymes like superoxide dismutase 
(Szeto, 2006). Otherwise, it induces profound damage of important biological molecules like 
DNA, lipids and proteins as observed in brain tissue of PD patients (Dauer et al., 2003). 
Complex I deficiency was found to increase ROS production, likely because of the diminished 
electron transfer and the resulting failure in the conversion of oxygen to water (Ramsay et al., 
1987) and in turn, ROS harms complex I subunits, as was observed in the frontal cortex of PD 
patients (Keeney et al., 2006) Additionally, glutathione depletion was found in the SNpc, too (Gu 
et al., 1998). 
Furthermore, DJ-1 (PARK7) mutations have been found to lead to increased ROS production, 
thereby causing autosomal-recessive PD (Andres-Mateos et al., 2007) and to be prevented by an 
overexpression of PINK1 (PTEN (Phosphatase and tensin homolog)-induced putative kinase 1) 
and Parkin as determined in cell culture (Irrcher et al., 2010). Interestingly, an overexpression of 
PINK1, in which mutations also cause autosomal-recessive forms of PD, can prevent the binding 
of aSYN to mitochondrial membrane and consequently the inhibition of mitochondrial fusion 
(Kamp et al., 2010). 
Importantly, neurons are particularly vulnerable to mitochondrial alterations due to their high 
dependence on energy and Ca2+ homeostasis, favoring an involvement of mitochondrial 
dysfunction in the pathogenesis of PD. However, it remains to be evaluated if these display an 
initial or secondary effect to PD pathogenesis and in which way several indicators, mentioned in 
the beginning, interact. 
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2. Aims of work  
The present work was accomplished to investigate the influence of mitochondrial 
polymorphisms on the PD pathogenesis in mice and to contribute understanding to the 
relevance of energy-dependent mechanisms in the context of PD.  
For this purpose, the well-known PD mouse model, tg-aSYN, was to be characterized to assess its 
histological, biochemical and behavioral profile in young and old age. Based on the results, the 
intention was to determine the effects of specific mitochondrial polymorphisms on this mouse 
model. Therefore, a newly generated mouse, tg-aSYN-mtNOD, was to be examined with respect 
to following questions. 
1. Do the mitochondrial polymorphisms lead to changes in histological, biochemical or 
behavioral characteristics of the mouse model such as: 
a. aSYN coverage as well as neuronal and microglial area in the cortex, 
b. intracerebral aSYN level, 
c. movement deteriorations and spatial orientation? 
2. Does the investigation of functional effects of the changed mitochondrial genome and its 
polymorphisms by respirometry point to differences in complex-dependent respiration 
between the background strains of the mouse models, tg-aSYN and tg-aSYN-mtNOD? 
A follow-up study based on the promising results was appointed to verify a transport of aSYN via 
the ABC transporter ABCC1 using two strategies. 
1. Does an ABCC1 knock-out mouse model display differences in intracerebral aSYN level 
and/or neuronal and microglial area in the cortex?  
2. Is the pharmacological activation of ABCC1 able to counteract the aSYN burden and 
neuronal decline present in the brain of tg-aSYN mice? 
In order to determine the influence of ABCC1 on the PD pathogenesis, a new mouse model was 
generated, the ABCC1 knock-out mouse, tg-aSYN-ABCC1-/-. 
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3. Material & Methods 
3.1  Material 
3.1.1 Antibodies 
 clone Company 
Anti-human α-Synulcein  5G4 aj roboscreen 
Glial Fibrillary Acid protein (GFAP) polyclonal DAKO 
Ionized calcium binding adapter molecule 1 (Iba1) polyclonal WAKO 
Anti-Neuronal Nuclei (NeuN) A60 Chemicon (Millipore) 
 
3.1.2 Chemicals 
 Company 
2-Mercaptoethanol  Carl Roth GmbH 
3-(N-morpholino)propanesulfonic acid  
(MOPS) 
Sigma-Aldrich 
α-Ketoglutarate Sigma-Aldrich 
Acetic acid  Carl Roth 
Adenosine diphosphate (ADP) Sigma-Aldrich 
Agarose  Biozym Diagnostik GmbH 
Antimycin A Sigma-Aldrich 
Ascorbate Sigma-Aldrich 
Atractyloside Sigma-Aldrich 
Azide Sigma-Aldrich 
Bovine serum albumin (BSA) SERVA Electrophoresis GmbH 
Calcium chloride (CaCl2) Merck KGaA 
Carbonyl cyanide-4-(trifluoromethoxy)- 
Phenylhydrazone (FCCP) 
Sigma-Aldrich 
citrate  
D-Glucose  Sigma 
Digitonin Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Merck KGaA 
Dithiothreitol (DTT) Sigma-Aldrich  
Ethanol 96 %  Carl Roth GmbH 
Ethidium bromide  Carl Roth GmbH 
Ethylenediaminetetraacetic acid (EDTA) Merck KGaA 
Ethylene glycol tetraacetic acid (EGTA) Sigma-Aldrich 
Glutamate Sigma-Aldrich 
Glycero-3-phosphate Sigma-Aldrich 
Guanidinhydrochloride  Carl Roth GmbH 
HCl  Carl Roth GmbH 
Heparin  Sigma-Aldrich 
Igepal CA630  Fluka Biochemika 
KCl  Carl Roth GmbH 
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KH2PO4 Merck KGaA 
Malate Sigma-Aldrich 
Mannitol Sigma-Aldrich 
Methanol  VWR 
Milk powder  Carl Roth GmbH 
MgCl2*(6H2O)  Carl Roth GmbH 
Nagarse Sigma-Aldrich 
NaCl  Carl Roth GmbH 
Na2CO3 Carl Roth GmbH 
NaH3  Carl Roth GmbH 
NaHCO3  Carl Roth GmbH 
Na2HPO4 Sigma-Aldrich 
Paraffin Paraplast  Leica Biosystems /Menarini 
PBS (10x)  Sigma-Aldrich 
Paraformaldehyde (PFA)  Carl Roth GmbH 
Proteinase K  Carl Roth GmbH 
PVDF membrane  Carl Roth GmbH 
Pyruvate Sigma-Aldrich 
RNAlater  Applied Biosystems 
Rotenone Sigma-Aldrich 
Succinate Sigma-Aldrich 
Sucrose Merck KGaA 
TEMED  Carl Roth GmbH 
N,N,N′,N′-tetramethyl-p-phenylenediamine  
(TMPD) 
Merck KGaA 
Thiethylperazine (Torecan®) Novartis 
Tris Carl Roth GmbH 
Tris-HCl  Carl Roth GmbH 
Tween 20  Merck 
Xylene  Carl Roth GmbH 
 
3.1.3 Equipment 
 Company 
BOND-MAX Autostainer Leica Microsystems GmbH/Menarini 
Centrifuge Universal 320R  Hettich  
Precellys® 1.4mm zirconium oxide beads Saphire bioscience 
Chip cuvette Analytic Jena AG 
Electrophoresis power supply EV 231 Consort bvba 
Embedding system Leica EG 1160  Leica Biosystems 
Feeding needle Fine Science Tools 
Freezer -20 °C  gorenje  
Freezer -80 °C  Kryotec  
Glass homogenizer WHEATON  
Histokinette STP 120  Mikrom 
Homogenisator SpeedMill PLUS  analytic jena  
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Microtome RM 2155  Leica Biosystems 
Mirax Midi  Zeiss 
OROBOROS oxygraph-2k  Oroboros Instruments 
Pannoramic MIDI  3DHistech  
ParadigmTM detection platform Beckman-Coulter/Molecular Devices 
Pole (Pole test) custom made 
Rotarod Ugo basile 
Scale Santorius  Santorius  
Scandrop  Analytic Jena AG 
SunriseTM  Tecan Group Ltd  
Syringes  Hamilton Messtechnik GmbH 
Thermocycler Biometra 
Thermoshaker EuroElone 
UVsolo TS Imaging System  Biometra GmbH 
Vortexer LMS VTX-3000L  LMS  
 
3.1.4 Kits 
 Company 
Bicinchoninic Acid Kit Sigma-Aldrich 
Bond-MaxTM Bond Polymer Refine  
Detection-Kit (DAB R30) 
Leica 
Complete Mini protease inhibitor cocktail  Roche Diagnostics 
GeneRuler 100 bp  Fermentas  
Human α-Synuclein Mono ELISA kit  ajRoboscreen 
Taq PCR Master Mix Kit Qiagen  
 
3.1.5 Primer 
 Sequence  
Human SNCA fwd 5’-TGTAGGCTCCAAAACCAAGG-3’ 
Human SNCA rev 5’-TGTCAGGATCCACAGGCATA-3’ 
MRP1 wild type fwd 5’-AAGACAAGGGCTTGGGATGC-3´ 
MRP1 rev 5´-CCATCTCTGAGATCTTGCCG-3´ 
MRP1 knock-out fwd 5´-GGAGCAAAGCTGCTATTGGC-3´ 
 
3.1.6 Software 
 Company 
Pannoramic Viewer 3DHISTECH Ltd 
BZ Analyzer Keyence 
Prism 6 GraphPad Software Inc. 
JMP 9 SAS institute 
R 3.0.2  R Development Core Team 
Axio Vision Zeiss 
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3.2  Methods 
3.2.1 Mouse models & Husbandry 
All mice used for the accomplishment of this study were housed in climate-controlled 
environment on a 12 h light/dark cycle with free access to rodent food (SNIFF, Germany) and 
water. All experiments were conducted in accordance to the European Union and the state law 
of the government of Saxony-Anhalt and approved by the local animal ethics committee. 
C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and provide the 
genomic background of the used transgenic mouse strains. They serve as control (Ctrl) 
throughout the entire work. 
Tg-aSYN mice were obtained from and described earlier by Kahle et al. (2001) and carry the 
human transgene aSYN with ‘A30P’ mutation, which is expressed under the neuron specific 
Thy1 (thymocyte differentiation antigen 1) promoter (Kahle et al., 2001), ensuring a robust 
expression of human aSYN with ‘A30P’ mutation.  
To generate the mtDNA conplastic strain tg-aSYN-mtNOD, an inbred mouse strain (NOD/LtJ) 
purchased from Jackson Laboratory which has been sequenced previously was used (Yu et al., 
2009). Female NOD/LtJ mice were mated with male C57BL/6J mice and backcrossed for more 
than ten generations to ensure mice to have the genomic DNA of C57BL/6J mice and the 
mitochondrial DNA of NOD/LtJ mice. Afterwards, male aSYN (A30P)-B6 mice became crossed to 
females of the conplastic strain to generate tg-aSYN-mtNOD mice.  
For the respirometry experiments, mice without any potein overexpression but with specific 
genomic and mitochondrial background i.e. C57BL/6J respectively mtNOD mice were used.  
The generation of the tg-aSYN-ABCC1-/- mice was realized by crossing previously described 
tg-aSYN mice with FVB.129P2-Abcc1atm1Bor N12 (Abcc1-/-) mice (Taconic Farm Inc., Denmark) 
for at least 9 generations to ensure a pure C57BL/6J background.  
3.2.2 Genotyping  
In order to control breeding conditions and to ensure the expected human aSYN overexpression 
respectively successful knock-out of ABCC1 in every single mouse, genotyping was essential. 
Here, the presence of the human transgene respectively the knock-out of the transporter in the 
murine genome was confirmed by polymerase chain reaction (PCR).  
 Mouse tail preparation 3.2.2.1
Once the mice reached an age of 20 days, part of their mouse tail was captured, snap-frozen and 
denatured over night at 55°C using lysis buffer. Digestion of tissue was provided by addition of 
proteinase K (Carl Roth) leading to the release of DNA. The enzyme was then inactivated at 95°C 
for 30 minutes and the mixture was centrifuged for 10 minutes with 14000 rpm prior to PCR. 
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Table 3: Composition of Lysis buffer 
 Concentration 
Tris pH 9 10 mM 
KCl 1 M 
Igepal CA-630 0.4 % (v/v) 
Tween 20 0.4 % (v/v) 
Aqua dest. to bring to volume 
 Polymerase chain reaction (PCR) 3.2.2.2
PCR is a commonly used method to amplify certain genes in vitro for different purposes. In this 
work PCR was used to confirm a specific genome status in mice. Human aSYN overexpression 
respectively ABCC1 knock-out was proved using a PCR kit (Taq PCR Master Mix Kit, Qiagen) and 
specific primers (see 3.1.5). A master mix was prepared as follows:  
 
Table 4: Pipette scheme PCR Master Mix for the detection of human aSYN 
 
concentration  
[pmol/µL] 
Volume  
[µL] 
H2O  5.06 
Taq Master mix  
(PCR kit) 
 5.5 
primer SNCA fwd 0.2 0.22 
primer SNCA rev 0.2 0.22 
   
Master mix total  11 
DNA  1 
final  12 
 
Table 5: Pipette scheme PCR Master Mix for the detection of ABCC1 
 
concentration  
[pmol/µL] 
Volume  
[µL] 
H2O  4.71 
Taq Master mix  
(PCR kit) 
 5.5 
primer MRP1 wild type fwd 1 0.44 
primer MRP1 rev 0.55 0.24 
primer MRP1 knock-out fwd 0.25 0.11 
   
Master mix total  11 
DNA  1 
final  12 
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The reactions were developed in a thermocycler under following conditions:  
Table 6: Cycler protocol for the amplification of human aSYN 
step temperature time cycle number 
initial denaturation 95°C 5 min  
denaturation 95°C 45 sec 
 
35x 
annealing 58°C 60 sec 
elongation 72°C 60 sec 
final elongation 72°C 5 min  
 4°C ∞  
 
Table 7: Cycler protocol for the amplification of ABCC1 
step temperature time cycle number 
initial denaturation 95°C 5 min  
denaturation 95°C 45 sec 
 
35x 
annealing 62°C 60 sec 
elongation 72°C 90 sec 
final elongation 72°C 5 min  
 4°C ∞  
 
 Agarose gel electrophoresis 3.2.2.3
PCR products were loaded on a 2 % agarose gel prepared with TAE buffer containing 
3 µL ethidium bromide/100 µL. A pre-stained protein ladder was used to estimate the size of 
fragments. If transgenes were present, a band at ~250 bp became visible for aSYN and at 900 bp 
for wildtype- ABCC1 respectively at 600 bp if ABCC1 was knocked-out. Heterozygous ABCC1 
knock-out mice display bands at either size. The gel was documented (UVsolo TS Imaging 
System, Biometra GmbH). 
Table 8: Composition of TAE (Tris-Acetate-EDTA) buffer 
 Concentration 
Tris 2 M 
Acetic acid 1 M 
EDTA 50 mM 
pH 8.4 
Aqua dest. to bring to volume 
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3.2.3 Behavioral tests 
To control the development of the mice, each mouse was weighed before behavioral tested.  
 Rotarod 3.2.3.1
Rotarod is a widely used method to conduct testing of coordination and motor function. The 
rotarod (Ugo basile, Italy) consists of a rotating rod (Ø 3cm) with a rough surface which is 
divided into 5 parts and thus allows testing five mice in parallel. Mice falling off the rod 
automatically trigger a switch which stops time measurement. 
First, mice were trained on the rod. They had to walk at a constant speed of 4 rpm for one 
minute without falling. If passed, they were given a recovery time of at least 30 minutes and 
afterwards performed three consecutive trials with accelerating speed (4-32 rpm) for 4 minutes 
and with inter-trial intervals of at least 30 minutes for recovery. The time after which each 
mouse fell off the rod was documented whereas those passing 4 minutes without falling were 
removed and 240 seconds set as maximum duration. The time of the first passive rotation, that 
is rotation without actively walking but gripping on the rod, was also documented. The protocol 
was adopted and adjusted to meet own requirements (Tabuse et al., 2010; Freitag et al., 2003; 
Morris et al., 2011). 
 Pole test 3.2.3.2
The Pole test is a common method to evaluate movement disorders in mice that are based on 
basal ganglia function, such as bradykinesia (Ogawa et al., 1985). The experiments were carried 
out according to several existing protocols with minor adaptions (Sedelis et al., 2001; Fernagut 
et al., 2003; Fleming et al., 2004; Matsuura et al., 1997). A wooden pole (50 cm height, 0.8 cm 
diameter) with a rough surface was placed into the home cage of the tested mouse. Cage mates were 
removed during the time. The time measurement was started as soon as the mouse was place head 
upwards near the top of the pole. Two time points were determined: First, when they performed a turn 
of 180° (head facing downwards); second, when the mice reached the floor with all four limbs. On the 
first day, each mouse was habituated and trained three times on the pole with a recovery time of at 
least 10 minutes in between. On the second day they had to perform five consecutive trials with inter-
trial intervals of at least 10 minutes. Data of mice which slipped or fell off the pole were not taken into 
account.  
3.2.4 Treatment with Thiethylperazine 
The treatment of tg-aSYN and tg-aSYN-ABCC1-/- mice with thiethylperazine (Torecan®, 
Novartis) was conducted by oral gavage using a feeding needle (20 gauge). Thus, a standardized 
volume of thiethylperazine could be administered into the esophagus of each mouse in a fast and 
painless manner. Mice were treated daily from Monday till Friday, starting at an age of 50 days 
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until reaching 100 days of age. The weekend was set as recovery time. The application dose for 
this study was 15 mg/kg body weight thiethylperazine (human dosage) or a similar volume of 
water as control.  
3.2.5 Tissue preparation 
Mice were sacrificed by cervical dislocation and perfused transcardially with ice cold PBS 
(phosphate-buffered saline) (pH 7.4). One brain hemisphere was transferred into 4 % 
paraformaldehyde (for immunohistochemical analyses) or into ice cold MSE-A (for isolation of 
mitochondria, 3.2.6.3) while the second hemisphere was snap-frozen in liquid nitrogen and 
stored at -80°C. 
Table 9: Composition of PBS (pH 7.4) 
 
 
 
 
 
3.2.6 Biochemical analyzes 
 Total protein quantification via spectrophotometry 3.2.6.1
The protein content in samples was determined by spectrophotometric measurements (Scandrop, 
Analytic Jena AG, Germany). Therefore, 4 µL sample was applied onto a chip cuvette and the 
absorption of light with the wave length of 280 nm was measured and normalized to 320 nm. The 
concentration was calculated automatically according to the Beer-Lambert law. 
 Enzyme-linked immunosorbent assay (ELISA) 3.2.6.2
To biochemically analyze the amount of monomeric and higher molecular forms of aSYN, ELISA 
measurements were performed. Therefore, snap-frozen mouse brains were dosed with 500 µL 
RNAlater (Applied Biosystems) and thawed gently on ice for at least one hour. The brain was 
afterwards homogenized with four ceramic beads for 30 seconds using a homogenizer 
(Homogenisator SpeedMill PLUS, analytic jena). After a short centrifugation step, a part of the 
homogenized brain and one ceramic bead were transferred into 20 volumes (w/v) carbonate 
buffer and homogenized again for 20 seconds. This solution was centrifuged for 45 minutes at 
14000 rpm and 4°C. The supernatant was captured and denoted carbonate fraction. This 
fraction presents the soluble monomeric aSYN species. The remaining pellet was further used 
and mixed with 8 volumes (w/v) 5 M guanidine hydrochloride buffer, calculated from the initial 
tissue weight. The solution was allowed to mix gently at room temperature for 3 hours before 
 Concentration 
NaCl 137 mM 
KCl 2.6 mM 
Na2HPO4 10 mM 
KH2PO4 1.8 mM 
Aqua dest. to bring to volume 
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centrifuged again for 45 minutes at 14000 rpm and 4°C. The supernatant was collected as 
guanidine fraction, containing aggregates and higher molecular aSYN forms. The fractions were 
stored at -20°C until further usage. ELISA was performed according to the manufacturer’s instruction 
using samples diluted 1:30,000 in dilution buffer (MONO kit, ajRoboscreen, Germany). The bound 
HRP-coupled antibody complex was visualized by TMB/H2O2 staining and absorption measurement 
using a PARADIGM spectrophotometer (Beckman-Coulter/Molecular Devices, Germany).  
The optical densities of the standards were plotted against the aSYN concentration using the five-
parameter logistic equation standard curve. The aSYN concentration of unknown samples was 
interpolated from this curve. 
Table 10: Composition of Carbonate buffer (pH 11.5) 
 Concentration 
Na2CO3 100 mM 
NaCl 50 mM 
Aqua bidest. to bring to volume 
protease in- 
hibitor cocktail 
add freshly  
(1 pill/10 mL) 
 
Table 11: Composition of Guanidine buffer (pH 8) 
 Concentration 
Guanidine/HCl 5 M 
Tris/HCl 50 mM 
Aqua bidest. to bring to volume 
 
 Isolation of mitochondria 3.2.6.3
The isolation of mitochondria was performed as described by Gellerich et al. (Gellerich et al., 
2008) following a modified protocol of Clark and Nicklas (Clark et al., 1970).The execution of 
this method and the following respiratory measurement were done as part of a master thesis 
project (Zschiebsch, 2012, Master thesis). 
The freshly prepared and in MSE-A buffer transferred mouse brain hemispheres (without 
cerebellum) were roughly hackled and homogenized accurately in 5mL MSE-A buffer containing 
0.05 % nagarse using glass homogenizer. The MSE-A buffer is used to provide a specific chemical 
milieu for the mitochondria, as it contains not only EGTA (ethylene glycol tetraacetic acid) but 
also DTT (Dithiothreitol), which protects thiol groups against inactivation. The homogenates 
were further diluted with 20 mL MSE-A and centrifuged at 4000 rpm for 4 minutes at 4°C. The 
supernatant was filtered through a filter cloth and centrifuged again at 10500 rpm and 4°C for 
10 minutes. The remaining pellet, containing the mitochondria, was filtered again and thus 
separated from cell debris. Afterwards, it was resuspended in 5 mL MSE-A containing 0.02 % 
digitonin in order to break up membranes and release the mitochondria. The solution was 
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centrifuged in 20 mL MSE-A at 10500 rpm and 4°C for additional 10 minutes. The pellet was 
resuspended in 100 µL MSE-B and stored at 4°C. 
 
Table 12: Composition of MSE-A (pH 7.4) 
 Concentration 
Mannitol 225 mM 
Sucrose 75 mM 
MOPS 20 mM 
EGTA 1 mM 
DTT 0.5 mM 
Aqua dest. to bring to volume 
  
Table 13: Composition of MSE-B (pH 7.4) 
 Concentration 
Mannitol 225 mM 
Sucrose 75 mM 
MOPS 20 mM 
EGTA 0.1 mM 
DTT 0.5 mM 
Aqua dest. to bring to volume 
 
 Total protein concentration quantification via BCA 3.2.6.4
Protein concentration was determined using the Bicinchoninic Acid Kit (Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany) and the SunriseTM Reader (Tecan Group Ltd., Männedorf, 
Switzerland). The protocol was performed according to manufacturer’s instructions. The samples and 
standards were diluted in 10 mM PBS (phosphate buffered saline) and PBS served as blank value as 
well. Dilutions of 1:50 and 1:100, respectively, were used for mitochondrial protein samples, which 
were measured in duplicates. 
3.2.7 Respirometry 
Respirometry is a method used to analyze the functionality of mitochondria and to identify 
changes in single respiratory chain complexes. The whole experiment was conducted using 
OROBOROS oxygraph-2k (Oroboros Instruments, Innsbruck, Austria) equipped with Clark-type 
oxygen electrodes. To study different rates of respiration depending on specific substrates addition and 
the corresponding differences in complex-dependent oxygen consumption, mitochondria (0.06 mg 
protein/mL) were added to the measurement chamber containing BIM-1000 (brain incubation 
medium). This medium enriched with 11 nM Ca2+ was heated to 30°C. The oxygen concentration in 
air-saturated medium was considered to be 200 nmol O2/mL at 95 kPa. 
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For the accomplishment of this study four different experimental approaches were chosen, each 
comprising a specific sequential order of substrate addition leading to the imitation of certain 
physiological conditions in the cell (see Table 14) (based on (Trumbeckaite et al., 2001; Gellerich 
et al., 2002; Gellerich et al., 2008; Gellerich et al., 2012; Krebiehl et al., 2010)). 
Table 14: Order of substrate addition according to the four experimental protocols 
Protocol I  
“COX I” 
Protocol II  
“COX II” 
Protocol III 
“ATPase” 
Protocol IV 
“CI/II/III” 
BIM-1000 BIM-0 
2 mM malate 2 mM malate 2 mM malate 2 mM malate 
10 mM glutamate 10 mM α-ketoglutarate 10 mM pyruvate 10 mM glutamate 
0.06 mg/ mL mitochondria 
2 mM ADP 2 mM ADP 100 µM ADP 100 µM ADP 
200 µM Ca2+ 200 µM Ca2+ 2 mM ADP 2 mM ADP 
100 µM Ca2+ 100 µM Ca2+ 10 mM glutamate 10 mM pyruvate 
10 mM pyruvate 10 mM pyruvate 10 mM succinate 10 mM succinate 
1.5 µM rotenone 1.5 µM rotenone 4x 25 nM FCCP 1.5 µM rotenone 
10 mM glycerol-3-
phosphate 
10 mM glycerol-3-
phosphate  
125 µM 
atractyloside 
10 mM succinate 10 mM succinate   
5 µM antimycin A 5 µM antimycin A   
2 mM ascorbate 
500 µM TMPD 
2 mM ascorbate 
500 µM TMPD   
5 mM azide 5 mM azide   
 
To start with protocol I (and II), mitochondria were incubated in BIM-1000 in the presence of 
10 mM glutamate and 2 mM malate. The addition of 2 mM ADP (adenosine diphosphate) led to 
the maximal possible respiration reachable with these substrates, denoted as state 3glu/mal. This 
state was further stimulated by two subsequent Ca2+ additions, simulating the activation of 
mitochondrial substrate supply by extramitochondrial Ca2+ (Gellerich et al., 2012). The addition 
of 10 mM pyruvate culminated in the maximal complex I dependent respiration, state 3compl.I. The 
next step included the addition of 1.5 µM rotenone, a well-known complex I inhibitor, to 
completely repress complex I dependent respiration. After that, the addition of 10 mM glycerol-
3-phophate adjusted the respiration to state 3G3P and the following succinate adding led to the 
maximal complex II dependent respiration, state 3succ. To fully inhibit complex III dependent 
respiration and with that also complex II, antimycin A was given to the measurement. Now, 
ascorbate/TMPD (N,N,N′,N′-tetramethyl-p-phenylenediamine) allows the measuring of the 
maximal respiration emerging from the oxidation of reduced cytochrome c by cytochrome c 
oxidase (complex IV). After the addition of azide, an inhibitor of cytochrome c oxidase, the 
respiration rate could be corrected by subtracting this value.  
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Protocol II starts from a different premise but follows the same procedure thereafter. The 
approach begins with the addition of 10 mM α-ketoglutarate instead of glutamate.  
Protocol III and IV were performed in BIM-0, without EGTA, which means a larger endogenous 
Ca2+ content. This leads to the complete activation of Ca2+ stimulated substrate supply. Protocol 
III starts with 10 mM pyruvate and 2 mM malate, followed by the addition of small amounts of 
ADP to adjust a partial activation of respiration, which drops after a short while again to a state 
referred to as state 4. The subsequent supply of 2 mM ADP leads to the reaching of state 3pyr/mal, 
whereas the addition of 10 mM glutamate adjusts the maximal complex I respiration rate, state 
3compl.I. Again, added succinate culminates in state 3compl.III. To exclude the possibility of a 
dysfunctional ATPase and a resulting limitation of the oxidative phosphorylation, FCCP was 
added gradually to uncouple the oxidative phosphorylation.  
The last protocol starts with 10 mM glutamate and 2 mM malate and the sequential adding of 
ADP leading to state 4 and state 3glu/mal, as described before. 10 mM pyruvate adjusts the state 
3compl.I again. The supply of succinate allowed the determination of state 3compl.III and rotenone 
inhibits, as seen before, the complex I dependent respiration and allows so the examination of 
state 3succ. Finally, 125 µM atractyloside allows the registration of state 4atr, in which no ADP is 
available as this glycoside prevents the transport of ADP.  
Furthermore, several ratios and special properties were analyzed from the resulting data. The 
oxygen consumption was calculated from the time derivative of oxygen concentration 
(DATGRAPH Analysis software, OROBOROS INSTRUMENTS, Innsbruck, Austria). Data are given 
in nmol O2/min/mg mitochondrial protein. 
Table 15: Composition of BIM-1000 (pH 7.4) 
 
 
 
 
 
 
Table 16: Composition of BIM-0 (pH 7.4) 
 Concentration 
Mannitol 120 mM 
MOPS 40 mM 
KH2PO4 5 mM 
KCl 60 mM 
MgCl2 5 mM 
Aqua dest. to bring to volume 
 Concentration 
Mannitol 120 mM 
MOPS 40 mM 
KH2PO4 5 mM 
KCl 60 mM 
MgCl2 5 mM 
EGTA 1 mM 
Aqua dest. to bring to volume 
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Table 17: substrates and their solvents used for respirometry 
substrate solvents 
α-ketoglutarate Tris-HCl (500 mM) 
adenosine diphosphate ultra-pure water 
ascorbate ultra-pure water 
antimycin A ethanol  
atractyloside DMSO 
azide ultra-pure water 
calcium chloride ultra-pure water 
FCCP (Carbonyl cyanide-4- 
(trifluoromethoxy)phenylhydrazone) 
ethanol  
glutamate Tris-HCl (500 mM) 
glycerol-3-phosphate BIM-1000 
malate Tris-HCl (500 mM) 
pyruvate Tris-HCl (500 mM) 
rotenone ethanol 
succinate Tris-HCl (500 mM) 
TMPD (N,N,N′,N′-tetramethyl-p- 
phenylenediamine) 
ultra-pure water 
 
3.2.8 Immunohistochemistry 
For immunohistochemical analyzes, 72 hour paraformaldehyde-fixed brain hemispheres were 
paraffin-embedded and de-hydrated according to the following scheme: 
Table 18: Dehydration protocol for paraformaldehyde-fixed brain hemispheres 
reagent time [min] 
Formalin 4 % buffered 5 
Ethanol 70 % 180 
Ethanol 80 % 60 
Ethanol 80 % 120 
Ethanol 90 % 60 
Ethanol 90 % 60 
Ethanol abs. 120 
Ethanol abs. 120 
Xylene 120 
Xylene 120 
Paraffin 60°C 240 
Paraffin 60°C 240 
  
Afterwards, the tissue was cut into 4 µm thick coronal sections using a microtome (Leica 
Biosystems). The following de-paraffinization and re-hydration, as well as immunostaining 
procedure was performed with the BOND-MAX Autostainer (Leica Microsystems 
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GmbH/Menarini). In order to block endogenous peroxidases and to retrieve epitopes, the 
sections were pretreated, for 5min with citrate, EDTA buffer pH 8.5 or enzymatically according 
to the manufacturer’s instructions of the used antibodies (see 3.1.1). The antibodies were 
incubated for 30 min with the following dilutions: aSYN clone 5G4 (1:6000), NeuN (1:500), Iba1 
(1:1000) and GFAP (1:500) and were detected with BOND-MAX Bond Polymer Refine Detection 
kit (DAB R30). Additionally, these sections were counterstained with hematoxylin leading to a 
strong blue staining of the cell nucleus. The slides with four sections each were digitalized by 
Mirax Midi automated slide scanner with a resolution of 230 nm (Scheffler et al., 2011). To 
capture microscopic images for further analysis, the panoramic viewer (3DHISTECH Ltd., 
Hungary) and BZ Analyzer (Keyence, Germany) were used. 
 Semi-quantitative Analysis of Immunohistochemistry 3.2.8.1
To examine possible differences in microglia response and distribution as well as quantity of 
neurons, the partial area covered by Iba1-positive cells or the amount of NeuN-positive cells, 
respectively, in the cortex of all mouse strains was determined by using the Hybrid cell count 
function of the BZ Analyzer (Keyence, Germany). Four images were taken using the same 
magnification from four different slices of the same animal brain. The ratio of stained cell area to 
unstained cortex area was calculated and the mean value was used for the evaluation. 
3.2.9 Statistics 
Statistical analyses of the ELISA, Immunohistochemistry and Respirometry data were performed 
using GraphPadTM prism 6 and one-way ANOVA followed by Sidak’s multiple comparison test 
respectively Kruskal-Wallis test followed by Dunn’s multiple comparison test if normal 
distribution was not given. Significance was reached when p ≤ 0.05. 
Statistical analyzes of behavioral test were performed by the Institute for Mathematical 
Stochastic using JMP 9 (SAS institute, Heidelberg, Germany).  
To evaluate the rate of censoring in the rotarod data set, one-way ANOVA followed by 
Bonferroni’s multiple comparison test was used. Variance stabilizing transformation of data 
(arcsine-square root transformation) did not change the outcome of statistical analysis in this 
case; therefore the raw data was used instead. Significance was reached if p < 0.05.  
The Quantile-Quantile plot of the rotarod data shows that these are distributed normally until 
reaching the censoring cut-off time point. Additional analyses were performed using R 3.0.2 
(R Development Core Team, www.r-project.org) and the package ‘lmec’. This function fits a 
‘Linear Mixed-Effects Models with Censored Responses’ as is provided by this data set. Analyzes 
was performed for the time frame of 9 to 41 weeks and for mid-age time points (25-33 weeks). 
No single time points were analyzed. Significance was reached if p < 0.05.  
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The ‘pole test’ data set was non-parametrically transformed to mean ranks to ensure a better 
adjustment to normal distribution and fitted to a linear mixed model with fixed effects for 
genotype and random effects for animals. Statistical analyzes were performed using the REML 
(restricted maximum likelihood) approach and additional two-sided t-test with adjusted degrees 
of freedom to determine differences only for the data of main interest, collected between 25 and 
33 weeks of age and between 37 and 41 weeks of age, respectively. No single time points were 
analyzed. Here again, significance was reached if p < 0.05. 
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4. Results 
4.1 Characterization of the tg-aSYN mouse model with respect to PD 
Before starting the comparison of tg-aSYN and tg-aSYN-mtNOD mice it was important to 
characterize the PD mouse model concerning its histological, biochemical and behavioral profile. 
The following analyzes were conducted using heterozygous tg-aSYN mice at an age of 50 to 300 
days, C57BL/6J mice served as control.  
4.1.1 Phenotypical appearance of tg-aSYN mice 
The first observation of tg-aSYN and control mice did not reveal any obvious differences in 
phenotype and behavior. A previous study, which was part of a master thesis project, described 
that only a very small proportion of tg-aSYN displayed severe abnormalities in motor behavior, 
including weakness in the limbs and following gait instabilities as well as rigor in the hind limbs 
and paralysis. However, eye defects were detected in a large proportion of both mouse models, 
tg-aSYN and control mice, which were twofold higher in tg-aSYN mice. These findings were 
made using heterozygous and homozygous mice at an average age of approximately 300 days 
(Gröger, 2012, Master thesis). Thus, differences were expected not earlier than 300 d of age in 
tg-aSYN mice. Consistent with that, the examination of mice from 50 d to 300 d of age revealed 
no differences in phenotype or in development and weight.  
 
Figure 4: Weight of tg-aSYN and C57BL/6J mice from 9 to 41 weeks of age.  
Beside a tendency to less weight of tg-aSYN mice in the first 4 month of age, mice developed equally in both models. 
Data is presented as means ± SEM (n ≥ 5). 
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4.1.2 Immunohistological analyzes of tg-aSYN mice 
The immunostained coronal paraffin-embedded brain sections of tg-aSYN mice revealed an 
intensive signal in various anatomical structures of the brain. Here especially cortex, thalamus, 
hippocampus, basolateral amygdala, geniculate nucleus and zona incerta were stained most 
intensively. Hypothalamus, medial amygdala, dentate gyrus and other structures displayed only 
mild immunoreactivity. No Lewy body or Lewy neurit pathology was observed in the whole 
brain. 
 
Figure 5: aSYN-immunoreactivity of 50 d old and 300 d old tg-aSYN mice. 
Sections were immunostained using an anti-human-aSYN antibody, clone 5G4, and were counterstained for nuclei 
with hematoxylin. Localization of anatomical structures is shown in (A). Intense immunolabelling was detected in the 
neuropil of the cortex, hippocampus, thalamus, basolateral amygdala, geniculate nucleus and zona incerta, whereas 
staining of hypothalamus, mediale amygdala and detate gyrus was less intense. No distinct differences were observed 
between young (B) and old tg-aSYN mice (C). RSD, retrosplenial dysgranular cortex; Hc, hippocampus; MPT, medial 
pretectal nucleus; SC, somatosensory cortex; CA, cornu ammonis; DLG, dorsal lateral geniculate nucleus; T, thalamus; 
ZID, zona incerta, dorsal part; fr, fasciculus retroflexus; cp, cerebral peduncle; LV, lateral ventricle; BLP, basolateral 
amygdaloid nucleus, posterior part; BMP, basomedial amygdaloid nucleus, posterior part; DG, dentate gyrus; HT, 
hypothalamus; PMCo, posteromedial cortical amygdaloid area; Scale bar = 1000 µm.  
The comparison between young and old mice (50 d vs. 300 d) showed no distinct differences in 
signal intensity or alterations in anatomical structures stained. As a quantitative analysis was 
not possible due to the diffuse staining pattern, a visual estimation was made using enlarged 
images of cortex and hippocampus. (see Figure 6). The examination of the hippocampus 
revealed no obvious changes between the time points. However, it was possible to display that 
the CA2 region lacked aSYN expression in contrast to the moderate expression pattern in the 
CA1 and CA3 region. The enlarged cortex sections (see Figure 6 A,B) showed a vigorous labeling 
of neurons especially in the layer V and layer II/III whereas other layer only exhibited moderate 
expression.  
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Figure 6: Load of human aSYN in cortex and hippocampus of young and old tg-aSYN mice. 
The enlarged Cortex sections (A,B) revealed no obvious difference between 50 d (A) and 300 d (B) old tg-aSYN mice. 
Although fewer stained neurons in the cortex of 300 d old mice (B) indicated a less progressed degeneration process 
in younger mice (A). Arrows point to intensive stained neuron soma. The most vigorous staining was observed in 
layer V and II/III of the cortex (A,B). The pyramidal cells of the hippocampus displayed the most intensive staining in 
the CA1 and CA3 region whereas the CA2 region spared any labeling and was aSYN-negative (D,E). No staining was 
detectable in Ctrl mice (C). CA, cornu ammonis; Scale bar = 100 µm in A-B; 500 µm in C-E. 
Immune response and neuronal integrity in the cortices of tg-aSYN mice compared with control 
mice were investigated, since neurodegeneration in PD is accompanied by a marked cell loss and 
most often with a high number of activated microglia and astrocytes (Mosley et al., 2012). 
Microglia were immunostained against Iba1, neurons against NeuN and astrocytes against GFAP. 
A difference was solely detected in the intensity of neuronal staining. 300 days old mice showed 
a less pronounced NeuN immunoreactivity compared to young ones (see Figure 7 A-B). Iba1- 
and GFAP staining revealed no differences (see Figure 7 C-F). 
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Figure 7: Immunohistochemical analyses of young and old tg-aSYN mice. 
The panel shows paraffin-embedded sections of the cortex, immunostained using anti-NeuN (A,B), anti-Iba-1 (C,D) or 
anti-GFAP (E,F). The first columns display young tg-aSYN (A,C,E), the second columns old tg-aSYN mice (B,D,F) Young 
tg-aSYN mice (A) showed a more intensive NeuN-staining compared to old ones (B). Iba-1 staining showed a slightly 
stronger microglial activity in old transgenic mice (D) compared with young mice (C), whereas there were hardly any 
changes visible for GFAP staining (E,F). Scale bar = 100 µm (A-F). 
The notion of a more pronounced NeuN immunoreactivity in old tg-aSYN mice was confirmed by 
semi-quantitative analysis of the ratio of area covered by NeuN positive cells to cortex area (see 
Figure 8A). Young animals showed no differences in the quantity of neurons between both 
genotypes. However, old tg-aSYN mice displayed a significantly lower NeuN immunoreactivity 
than old control mice leading to about 35 % less cortex area covered by neurons (p=0.0248; see 
Figure 8A). The quantification of microglial area, revealed no difference (see Figure 8B). 
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Figure 8: Semi-quantitative analysis of immunohistochemistry. 
Analysis revealed a significant difference in neuron integrity between young and old mice and especially between old 
tg-aSYN and Ctrl mice (A). Examination of microglial response showed no difference between both mouse models (B). 
Data is presented as means ± SEM (n ≥ 5), *p≤0.05; **p≤0.01; ***p≤0.001 (one-way ANOVA followed by Sidak’s 
multiple comparison test)  
4.1.3 Behavioral study on tg-aSYN mice 
As PD is a progressive motor disorder, behavioral tests are the gold standard for estimating 
severity of the disease. Here the rotarod test and the pole test were used to assess different 
types of motor parameter.  
 Rotarod  4.1.3.1
A preliminary study was performed for the purposes of a master thesis and the results were 
used to set up the rotarod test. Prior to the present work it was found that tg-aSYN mice, 
determined from an age of 300 d, showed no significant differences compared to control mice 
until 450 days of age. After, there was a rapid decline in transgenic and control mice. A 
difference between young and old tg-aSYN mice was visible from 300 d of age (Gröger, 2012, 
Master thesis).  
To assess the course of behavior alterations starting from earlier time points, a new study was 
performed, using male heterozygous tg-aSYN and C57BL/6J (control) mice beginning from 
9 weeks of age and finished by the age of 41 weeks, with special focus on the mid-age time 
points (25-33 weeks).  
In order to minimize the usage of laboratory animals, mice were tested longitudinally. Previous 
tests showed that learning effects between the time points can be neglected. Nonetheless, these 
circumstances were considered in the statistical analysis. 
The first evaluation of the rotarod data set was conducted with respect to the percentage of 
censoring (see Figure 9). The cut-off-time in this study was set to 240 seconds and more mice as 
expected were able to stay on the rod for the duration of this period. 
Interestingly, no significant differences were found in the amount of censored data between 
tg-aSYN (34 %) and control mice (23 %) at mid-age time points, i.e. 25-33 weeks (see Figure 9).  
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Figure 9: Proportion of censored data in the rotarod data set. 
No differences between tg-aSYN and Ctrl mice were found between 25 and 33 weeks of age. Data is presented as mean 
diamonds and x-axis proportional (n ≥ 15, male) (one-way ANOVA followed by Bonferroni’s multiple comparison 
test). 
Further statistical analyses required a better fitted model (confer 3.2.9) to solve the main 
questions (I to III) arising from the data:  
I) Is there a difference between both groups? 
II) Has age a significant influence on the performance of the groups? 
III) How distinct are the differences between both groups in mid-age time points? 
The comparisons, calculated for the maximal time latency the mice were able to stay on the rod 
as well as for the time until the first passive rotation, revealed no significant differences between 
tg-aSYN and control mice (see Figure 10). A linear influence of age was calculated to control for 
age-related effects. Notable, age was found to have a strong influence on the performances of 
tg-aSYN and control mice, as they improved their performance with advancing age in both 
parameter (p=0.046, p=0.0018). 
 
Figure 10: Age-dependent alteration in motor behavior of tg-aSYN and C57BL/6J mice. 
Latency of rotarod performances (A) and time of first passive rotation (B) of tg-aSYN and Ctrl mice (C57BL/6J) 
showed no differences until the age of 300 d. However, age had a significant impact on both performances in both 
animal groups. Data is presented as means ± SD (n ≥ 5, male) (Linear Mixed-Effects Models with Censored Responses, 
LMEC).  
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 Pole Test 4.1.3.2
To determine possible differences in the ability of orientation and to assess alterations in motor 
performance, the pole test was performed. For the accomplishment of this study, male 
heterozygous tg-aSYN and C57BL/6J (control) mice were used starting from the age of 50 d until 
the age of 300 d was reached.  
While mice had to turn 180° on the top of the pole and had to climb down, first observations 
were made on their performance. Unsuccessful attempts (such as incomplete turn at the top and 
slipping) were not taken into account. Notably, these inadequate performances did not solely 
occur in the group of tg-aSYN mice, but scatter randomly in both groups. Therefore, no 
differences were seen in the accomplishment of turning respectively climbing down the pole. 
Surprisingly, no differences were observable in the time of the orientation performance of the 
pole test (p=0.89). Even more interestingly, control mice took significantly longer to climb down 
at late time points (37-41 weeks) in contrast to tg-aSYN mice (p=0.001) but not at mid-age time 
points from 25 to 33 weeks (p=0.06). 
 
Figure 11: Changes in pole test performances of tg-aSYN and C57BL/6J mice. 
No significant alterations were detected in time-until-turn-latency (A) until old age. The climb performance revealed 
surprisingly a worse performance of Ctrl mice when compared to tg-aSYN mice (B). Data is presented as means ± SEM 
(n ≥ 5, male). (restricted maximum likelihood (REML) approach and additional two-sided t-test with adjusted degrees 
of freedom). 
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4.2 Influence of specific mitochondrial polymorphism on aSYN 
pathology in tg-aSYN mice 
To determine the influence of distinct mitochondrial polymorphism on the pathology of tg-aSYN 
mice, a novel mouse model was generated, the conplastic mouse – tg-aSYN-mtNOD. Different 
immunohistological, biochemical and behavioral analyses were performed in order to evaluate 
differences and similarities of both mouse models. 
4.2.1 Immunohistological analyzes of tg-aSYN-mtNOD mice 
Immunohistological analyzes of tg-aSYN-mtNOD mice, stained with anti-aSYN clone 5G4, 
revealed no obvious differences compared to tg-aSYN mice (see Figure 13 B-C). The stained 
structures were consistent with the formerly described immunoreactivity (confer 4.1.2).  
 
 
Figure 12: aSYN-immunoreactivity in 300 d old tg-aSYN and tg-aSYN-mtNOD mice. 
Hemisphere sections were immunostained using an anti-human-aSYN antibody, clone 5G4, and were counterstained 
for nuclei with hematoxylin. Localization of anatomical structure is shown in (A). No vigorous differences are 
observable between tg-aSYN (B) and tg-aSYN-mtNOD mice (C). RSD, retrosplenial dysgranular cortex; Hc, 
hippocampus; MPT, medial pretectal nucleus; SC, somatosensory cortex; CA, cornu ammonis; DLG, dorsal lateral 
geniculate nucleus; T, thalamus; ZID, zona incerta, dorsal part; fr, fasciculus retroflexus; cp, cerebral peduncle; LV, 
lateral ventricle; BLP, basolateral amygdaloid nucleus, posterior part; BMP, basomedial amygdaloid nucleus, posterior 
part; DG, dentate gyrus; HT, hypothalamus; PMCo, posteromedial cortical amygdaloid area; Scale bar = 1000 µm.  
However, a more intensive NeuN staining was observed in the cortex of 300 d old 
tg-aSYN-mtNOD mice compared to tg-aSYN mice (see Figure 13 A-B). Observable differences 
were not found in case of Iba1 and GFAP staining (see Figure 13 C-F). 
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Figure 13: Immunohistochemical analyzes of 300 d old tg-aSYN and tg-aSYN-mtNOD mice. 
The panel shows cortex sections of 300 d old tg-aSYN (left column) and tg-aSYN-mtNOD mice (right column). Stained 
with NeuN (A-B), the cortex of tg-aSYN-mtNOD mice (B) revealed a more intensive signal compared to tg-aSYN mice 
(A). No differences are visible upon Iba1 (C-D) and GFAP (E-F) staining between mouse models, tg-aSYN and 
tg-aSYN_mtNOD. Scale bar = 100 µm. 
As depicted in Figure 14A, the semi-quantitative analysis of the neuronal integrity showed a 
dramatic loss of neurons in 300 d old tg-aSYN-mtNOD mice compared to young ones, 
comparable to tg-aSYN and control mice. The above mentioned differences (confer 4.1.2) 
between tg-aSYN and control mice were not confirmed for tg-aSYN-mtNOD mice and the 
neuronal area was instead comparable to those of control mice (see Figure 14A). In contrast to 
the tg-aSYN mice which displayed only 65 % of the neurons that were found in the control group 
at the same age (p=0.0435), the tg-aSYN-mtNOD mice still had 95 % left.  
Interestingly, old tg-aSYN-mtNOD mice exhibited a 50 % greater proportion of microglial area in 
the cortex compared to control mice (see Figure 14B), indicating a significantly greater 
microglial response in the brain of 300 d old tg-aSYN-mtNOD mice (p=0.0301). Tg-aSYN mice 
showed an about 40 % increased microglial area, significance was not reached. 
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Figure 14: Semi-quantitative analysis of Immunohistochemistry in the cortex of tg-aSYN, tg-aSYN-mtNOD and 
C57BL/6J mice. 
Analysis showed rescued neuron integrity in case of old tg-aSYN-mtNOD mice compared to tg-aSYN mice with no 
differences to Ctrl mice (A). A greater proportion of microglia was detected in the cortex of 300 d old tg-aSYN-mtNOD 
mice compared to Ctrl mice (B). Data is presented as means ± SEM (n ≥ 5), *p≤0.05; **p≤0.01; ***p≤0.001 (one-way 
ANOVA followed by Sidak’s multiple comparison test) 
4.2.2  Determination of aSYN in tg-aSYN and tg-aSYN-mtNOD mice using ELISA  
To verify aSYN burden in tg-aSYN and tg-aSYN-mtNOD mice, ELISA was performed. As a 
quantitative analysis of the immunohistochemical staining was impossible and gave only little 
insight into the distribution of the aggregated aSYN species labeled with anti-aSYN clone 5G4, 
the amount of aSYN in carbonate- and guanidine soluble fractions of the brain tissue of 50 d and 
300 d old tg-aSYN and tg-aSYN-mtNOD mice was determined using this method. 
 
Figure 15: ELISA measurements of aSYN in the brain of tg-aSYN and tg-aSYN-mtNOD mice.  
Mice with mitochondrial polymorphism showed a significantly greater amount of guanidine soluble aSYN in the late 
time point (B) compared to tg-aSYN mice, whereas the carbonate soluble aSYN revealed no differences (A). Notable 
was the unchanged amount of total aSYN between both time points. Data is presented as means ± SEM (n ≥ 6), *p≤0.05 
(one-way ANOVA followed by Sidak’s multiple comparison test) 
The measurement of carbonate soluble aSYN, which includes monomeric and small oligomeric 
forms of aSYN, showed no significant differences between young and old tg-aSYN and 
tg-aSYN-mtNOD mice and between the time points (see Figure 15A). 
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Higher molecular species of aSYN were quantified using the guanidine soluble fraction of the 
brain tissue containing of the non-soluble, aggregated respectively fibrillar forms of the protein. 
No differences were visible at 50 d of age (p=0.0635), whereas the 1.6-fold amount of aSYN was 
detectable in 300 d old tg-aSYN-mtNOD mice compared to tg-aSYN, leading to a significantly 
greater aSYN burden in these mice (p=0.036; see Figure 15B). 
4.2.3  Influence of mitochondrial polymorphisms on the behavior of tg-aSYN mice 
The behavioral study of tg-aSYN-mtNOD mice was performed simultaneously with the above 
mentioned examination of tg-aSYN mice and results and statistics were evaluated equally. 
Tg-aSYN-mtNOD mice were compared to tg-aSYN and control mice that were already presented 
in section 4.2.3. 
 Rotarod 4.2.3.1
Observations made during the rotarod performances of the tg-aSYN-mtNOD mice revealed no 
obvious differences in the implementation of the task compared to tg-aSYN mice that are worth 
to be further described. 
The first evaluation of data concentrated again on the proportion of censored data according to 
the cut-off time of 240 s in the rotarod method. A significantly greater proportion of data was 
censored in case of tg-aSYN-mtNOD mice in the mid-age time points 25-33 weeks compared to 
tg-aSYN mice (p=0.0016), indicating a better physiological fitness of these mice (see Figure 16). 
While 72 % of the gathered tg-aSYN-mtNOD data were censored, only 34 % of the tg-aSYN data 
fell into this category (as mentioned in section 4.1.3.1). 
 
Figure 16: Proportion of censored data collected using rotarod. 
Tg-aSYN-mtNOD mice displayed a significantly greater proportion of censored data (72 %) compared to tg-aSYN mice 
(34 %). Data is presented as mean diamonds and x-axis proportional (n ≥ 15, male) (one-way ANOVA followed by 
Bonferroni’s multiple comparison test). 
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The results of the latency time and the time until the first passive rotation showed again 
comparable results (see Figure 17A-B).  
In order to answer the same questions as described in section 4.1.3.1, the results were compared 
to the data of tg-aSYN and control (see Figure 10). The tg-aSYN-mtNOD mice performed 
significantly better in both tasks (p=0.016, p=0.032) with the most distinct results again at mid-
age time points between 25 and 33 weeks of age (p=0.00008, p=0.00011). Age has a significant 
influence on the performances of both tasks as mentioned before (p=0.0062, p=0.000072). Refer 
to Figure 17 for visualization.  
 
Figure 17: Motor performances of tg-aSYN, tg-aSYN-mtNOD and C57BL/6J mice. 
Using rotarod, a tremendous difference between tg-aSYN-mtNOD, tg-aSYN and Ctrl mice, respectively, was 
determined in mid-age time points of 25 to 33 weeks. Tg-aSYN-mtNOD mice performed significantly better in both 
tasks. Age had a significant influence on both performances in all mouse models. Data is presented as means ± SD 
(n ≥ 5, male) (Linear Mixed-Effects Models with Censored Responses, LMEC). 
 Pole test 4.2.3.2
The determination of the influence of distinct mitochondrial polymorphisms on the motor skills 
of tg-aSYN-mtNOD mice was additionally performed by pole test. The procedure and analysis 
was the same as described before (4.1.3.2). Tg-aSYN-mtNOD mice displayed a better orientation 
performance (time-until-turn-latency) compared to tg-aSYN and control mice in old age 
(p=0.0237), i.e. 37-41 weeks but not at mid-age time points (p≥0.06). The climb performance 
however revealed neither in mid-age nor in old age any differences between tg-aSYN and 
tg-aSYN-mtNOD mice (see Figure 18).  
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Figure 18: Influence of mitochondrial polymorphism on the pole test performance of tg-aSYN mice. 
Tg-aSYN-mtNOD displayed significantly better time-until-turn-latencies compared to tg-aSYN mice (A) but no 
differences in climb performance were found (B). Data is presented as means ± SEM (n ≥ 5, male). (restricted 
maximum likelihood (REML) approach and additional two-sided t-test with adjusted degrees of freedom). 
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4.3  Respirometric measurements of isolated brain mitochondria  
To analyze the functional effects of mitochondrial polymorphisms in tg-aSYN-mtNOD mice, 
respirometric measurements were performed using high resolution respirometry. In this 
method, the oxygen consumption of isolated brain mitochondria is used as a parameter for the 
function of single complexes and the entire mitochondrion.  
In this study, mice of two different ages were used, 100 d and 200 d, which did not overexpress 
aSYN, i.e. mtNOD respectively C57BL/6J mice. As described in section 3.2.7, four different 
protocols (Table 14) served to assess parameters important for the understanding of the 
mitochondrial function. Substrates were added sequentially in order to measure complex-
dependent respiration rates and to calculate control ratios. These protocols were performed 
consecutively and each measurement resulted in a specific curve as displayed exemplarily in 
Figure 19.  
 
 
 
 
A 
B 
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Figure 19: Representative respirograms of old C57BL/6J mice. 
Shown is the sequential addition of substrate according to the four experimental approaches I-IV (A-D; see Table 14, 
page 37) and the resulting changes in O2 concentration (black line) and 02 flux (grey line), which were further 
evaluated. ADP, adenosine triphosphate; FCCP, Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; 
G3P, glycerol-3-phosphate; TMPD, N,N,N′,N′-tetramethyl-p-phenylenediamine 
4.3.1 Complex I- dependent respiration 
The complex I-dependent respiration rates were measured using all four protocols with 
different substrate compositions. No changes occurred in maximal complex I-dependent 
respiration (state 3compl.I) in young and old animals of both mouse models, C57BL/6J and mtNOD 
when using the substrate composition of malate, glutamate and pyruvate as provided by 
protocol I, III and IV. Interestingly, the results of protocol II showed a significantly greater 
oxygen consumption in case of young mtNOD mice compared to control mice (p=0.03; see Figure 
20A). 
In protocol I as well as II the additional supply of Ca2+ led to a vigorous increase of the 
respiration rate, even though the Ca2+ dependent activation was higher when malate and 
glutamate were provided (protocol I; 163 % of the state 3 respiration rate without 
Ca2+ stimulation) than with malate and α-ketoglutarate provided (protocol II; ~134 % of the 
starting state 3 respiration rate) (see Figure 20B). 
C 
D 
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Comparing the respiratory rates after Ca2+ stimulation, they were only elevated by the 
polymorphisms in young mtNOD mice in case of α-ketoglutarate (protocol II). Here, mtNOD mice 
show significantly greater oxygen consumption in comparison to control mice (p=0.04, see 
Figure 20B). 
It is important to note that the effect seen in the maximal complex I-dependent respiration rate 
(Figure 20A) is only a secondary effect of the stimulation caused by Ca2+ addition (Figure 20B).  
 
Figure 20: Complex I-dependent respiration of isolated brain mitochondria of mtNOD and C57BL/6J mice.  
Maximal complex I respiration (A) showed no differences between age and strains. The significantly increased 
respiration rate measured with protocol II was considered to be secondary effect to the increased Ca2+- dependent 
respiration illustrated in B. The stimulation of respiration using Ca2+ led to a vigorous increase in oxygen consumption 
with a larger extend in case of malate/glutamate as starting substrates (~163 %). However, the Ca2+- dependent 
increase that followed the protocol II approach was significantly greater in young mtNOD mice compared to young 
Ctrl mice (B). Data is presented as means ± SEM (n ≥ 14), *p≤0.05 (one-way ANOVA followed by Sidak’s multiple 
comparison test) 
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4.3.2 Complex II- dependent respiration 
To assess the complex II-dependent respiration, complex I was inhibited using rotenone in 
protocol I, II and IV with different starting substrates. This inhibition was necessary, because 
both complexes simultaneously deliver their electrons to ubiquinone. 
A further supply with glycerol-3-phosphate in protocol I and II led to an enhanced respiration 
(protocol I, 59 %; protocol II, 53 %) caused by an increased availability of reduction equivalents 
(FADH2) and adjusted the respiration to the maximal complex II-dependent respiration 
(state 3Compl.II) (see Figure 21A).  
Interestingly, the complex II-dependent oxygen consumption measured in the presence of 
α-ketoglutarate (protocol II) was generally smaller compared to glutamate (protocol I) as 
illustrated in Figure 21A. The state 3Succ rates (without glycerol-3-phosphate) based on 
protocol I revealed a decrease in 200 d old control mice compared to 100 d old ones (p=0.049), 
leading to a significantly smaller oxygen consumption in comparison with 200 d old mtNOD 
mice, too (p=0.0001; see Figure 21A). The tendency of this notion was also visible in the rates of 
protocol IV (p<0.1), but not in protocol II. However, in both approaches (I and II) young 
mtNOD mice showed a greater increase in oxygen consumption following the supply of 
glycerol-3-phosphate as compared to young control mice leading to a marked difference 
between old mtNOD and control mice (p=0.0016 for protocol I and p=0.0412 for protocol II; see 
Figure 21A). In conclusion, the most prominent difference between old mtNOD and control mice 
was seen in the maximal complex II-dependent respiration rate (with glycerol-3-phosphate) of 
protocol I and II. 
Furthermore, after preventing the transport of ADP by adding atractyloside and comparing the 
non-phosphorylating respiration (state 4Succ/Atr), similar results, as in Figure 21A, were obtained. 
Again, old control mice showed diminished complex II-dependent respiration rates in 
comparison to young control mice (p=0.0016) and old mtNOD mice (p=0.011; see Figure 21B). 
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Figure 21: Complex II-dependent respiration rates of mtNOD and C57BL/6J mice. 
The oxygen consumption measured in isolated brain mitochondria of 200 d old Ctrl mice was significantly lower 
compared to mtNOD mice when measurement was performed using protocol I (A, left) and tendentially lower when 
conducted with protocol IV (B, left). When supplied with glycerol-3-phosphate (G3P), old Ctrl mice displayed a 
significantly diminished respiration rate in comparison to mtNOD mice in both protocols (A). Even the non-
phosphorylating respiration revealed confirming results (B, right). Succ, Succinate; Atr, Atractyloside. Data is 
presented as means ± SEM (n ≥ 14), *p≤0.05; **p≤0.01; ***p≤0.001 (one-way ANOVA followed by Sidak’s multiple 
comparison test respectively Kruskall-Wallis test followed by Dunn’s multiple comparison test) 
Subsequently, the quotients of maximal complex I- and complex II-dependent respiration (in the 
following referred to as CI/CII ratio) were calculated for rates measured upon previous 
described protocols I, II and IV. This ratio is often used as indicator of complex I impairments 
and was changed by polymorphism. A significantly diminished CI/CII ratio for old mtNOD mice 
was found compared to old control mice (p=0.0074; protocol I) but no changes can be observed 
for protocol II and IV (see Figure 22). 
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Figure 22: Complex I/Complex II ratio calculated from measurements based on protocol I, II and IV of mtNOD 
and C57BL/6J mice.  
Significant changes occurred in old mtNOD mice compared to Ctrl based on the results achieved by protocol I. No 
changes were found in the same groups in protocol II and IV- dependent results. Data is presented as means ± SEM 
(n ≥ 14), *p≤0.05 (Kruskall-Wallis test followed by Dunn’s multiple comparison test) 
4.3.3 Complex III- dependent respiration 
The maximal complex III-dependent respiration (state 3compl.III) was achieved by the addition of 
substrates to reach maximal complex I respiration followed by the administration of succinate to 
obtain complex II respiration as realized by measurements upon protocol III and IV. No changes 
due to age or genotype occurred as illustrated in Figure 23. 
 
Figure 23: Complex III-dependent respiration rates of mtNOD and C57BL/6J mice. 
These rates were measured from isolated mitochondria of 100 d and 200 d old mtNOD respectively C57BL/6J (Ctrl) 
mice. No changes occurred between ages and strains. Data is presented as means ± SEM (n ≥ 12).  
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4.3.4 Complex IV- dependent respiration 
The next complex determined for respiration was complex IV, also referred to as 
cytochrome c-oxidase (COX). To ensure that only complex IV-dependent respiration was 
measured, complex I, II and III were fully inhibited by the addition of antimycin A. 
Complex IV-dependent respiration was then stimulated via the administration of TMPD, a 
powerful reduction equivalent that leads to the oxidation of cytochrome c by COX. Ascorbate 
regenerated TMPD with its antioxidant capacity. These steps were realized in protocol I and II. 
The respiration rate increased immediately and COX was afterwards inhibited by azide. The 
subsequently measured oxygen consumption was considered an artefact resulting from the 
auto-oxidation capacity of TMPD and was therefore subtracted from the complex IV-dependent 
respiration rates.  
As illustrated in Figure 24, a significant difference was found between young and old mtNOD 
mice when measured using protocol II (p=0.0093). Here, the oxygen consumption dropped 
about nearly 20 % with age. The results measured upon protocol I only displayed a reduction in 
respiration of 10 % in mtNOD and control mice. No changes occurred when comparing both 
mouse models.  
 
Figure 24: Complex IV-dependent respiration of mtNOD and C57BL/6J mice. 
Complex IV-dependent respiration was determined from isolated brain mitochondria of 100 d and 200 d old mtNOD 
and Ctrl (C57BL/6J) mice. The oxygen consumption in old mtNOD mice dropped about ~20 % compared to young 
ones when measured using protocol II. No changes were found between both strains. Data is presented as means ± 
SEM (n ≥ 14), *p≤0.05 (one-way ANOVA followed by Sidak’s multiple comparison test). 
COX is known to provide an excessive capacity which is higher compared to the maximal 
uncoupled respiration that can be determined by the addition of FCCP (see 4.3.5) (Gnaiger et al., 
1998). To examine possible differences between mtNOD and control mice, the excessive capacity 
of COX was calculated by forming the quotient of the complex IV-dependent respiration 
(protocol I and II) and the maximal ETC capacity (protocol III, see 4.3.5). 
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The excess capacity of COX was found to range between 1- and 1.3-fold of the maximal ETC 
capacity. No significant changes were observed between age and strains (Figure 25).  
 
Figure 25: The excess capacity of complex IV (COX).  
The excess capacity of COX related to the maximal respiration upon uncoupling with FCCP (4.3.5) revealed no changes 
between young and old Ctrl and mtNOD mice, respectively, nor between both strains. Data is presented as means ± 
SEM (n ≥ 9).  
4.3.5 Maximal respiration rate upon uncoupling with FCCP 
To examine the maximal capacity of the ETC and determine possible differences between 
mtNOD and control mice, it was necessary to uncouple the oxidative phosphorylation. This was 
achieved by the addition of FCCP. As a consequence, the proton flux is maximally increased. The 
addition of FCCP was performed step wise (protocol III) to prevent an inhibition of the ETC at 
certain concentrations and led to a peak that is displayed in Figure 26. The results revealed no 
differences between age and strains.  
 
Figure 26: Maximal capacity of ETC measured after uncoupling of the oxidative phosphorylation with FCCP. 
No changes between Ctrl and mtNOD and between ages were detectable. Data is presented as means ± SEM (n ≥ 11). 
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4.3.6 Resting states 
Non-phosphorylating respiration rates were calculated for complex I- and II-dependent oxygen 
consumption. In fact, the complex II-dependent non-phosphorylating respiration following 
protocol IV was already displayed in Figure 21B in 4.3.2. For the sake of completeness, it is 
illustrated in this section once more (Figure 27A, left columns). As already described before, the 
non-phosphorylating respiration revealed striking differences between young and old control 
mice (p=0.0016) and control and mtNOD mice at the age of 200 d (p=0.011). In contrast to that 
no changes in age or strain were observable when comparing the non-phosphorylating 
respiration of complex I that was measured due to limited respectively lack of adenine 
nucleotide concentration neither based on protocol III (Figure 27B) nor IV (Figure 27A). 
 
Figure 27: Different states of non-phosphorylating respiration for complex I- and complex II-dependent 
substrates. 
After inhibition of the adenine nucleotide-carrier with atractyloside, the non-phosphorylating respiration with 
succinate as substrate was larger in old mtNOD mice compared to Ctrl and between young and old Ctrl mice, too 
(described before in 4.3.2) (Figure 25A, left). State 4 respirations in the presence of 75 nM adenine-nucleotides 
(mainly ADP) showed no changes caused by age and polymorphism. Non-phosphorylating respiration without added 
adenine nucleotides revealed also no changes (Figure 25A for protocol IV, Figure 25B for protocol III). Data is 
presented as means ± SEM (n ≥ 11), *p≤0.05; **p≤0.01 (one-way ANOVA followed by Sidak’s multiple comparison 
test).  
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4.3.7 Respiratory Control Ratio  
The respiratory control ratio (RCR) was used to determine the relation of maximal respiration 
capacity in the presence of ADP (state 3) and respiration without ATP-synthesis (state 4). The 
RCR was calculated for the respective states of complex I (protocol III, Figure 28, left set of 
columns) and II (protocol IV, Figure 28, right set of columns). Based on this ratio it is possible to 
make statements concerning the importance and control of the oxidative phosphorylation over 
the ETC and how tight both are coupled. The RCR displayed by complex I-dependent respiration 
rates was not changed by age or polymorphism, whereas RCR based on complex II-dependent 
respiration rates showed a significant increase in 200 d old control mice compared to young 
ones (p=0.0028). Here again, no difference between both mouse models was visible (Figure 28). 
 
Figure 28: Respiratory control ratios (RCR) of mtNOD and C57BL/6J mice. 
RCR calculated for complex I-dependent respiration (Malate/ Pyruvate; protocol III) and complex II-dependent 
respiration (Succinate/Atractyloside; protocol IV). No changes were observable in complex I, whereas 200 d control 
Ctrl mice showed significantly greater RCR (Succ/Atr) values compared to young ones. Data is presented as means ± 
SEM (n ≥ 14), *p≤0.05; **p≤0.01 (one-way ANOVA followed by Sidak’s multiple comparison test). 
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4.4  Relevance of ABC transporter -ABCC1- activity on the aSYN 
pathology of tg-aSYN mice  
The increased complex II-dependent respiration found in mtNOD mice and the enhanced 
physiological performance of tg-aSYN-mtNOD mice led to the assumption that energy-
dependent mechanism might be impaired in mice overexpressing human mutated aSYN leading 
to the pathological phenotype of this PD mouse model. The aforementioned results suggest a 
decreased ATP supply which is very likely to influence several metabolic processes. 
Consequential, the present work aimed to verify whether aSYN is transported via the ABC 
transporter -ABCC1-, a prominent energy-dependent clearance mechanism approved for Aβ in 
AD mice (Krohn et al., 2011). 
A novel mouse model was created for this study, the ABCC1 knock-out mouse denoted 
tg-aSYN-ABCC1-/-.  
4.4.1 Consequences of the ABCC1 knock-out on the histology of the tg-aSYN mice 
Semi-quantitatively analyzed cortex section of 100 d old tg-aSYN and tg-aSYN-ABCC1-/- mice 
revealed no difference in neuronal- and microglial area (see Figure 29).  
 
Figure 29: Determination of neuronal- and microglial area in the cortex of 100 d old tg-aSYN and tg-aSYN-
ABCC1-/- mice. 
Semi-quantitative analyzes revealed no differences in neuronal area (A) and microglial area (B) in the cortex of 100 d 
old tg-aSYN compared to tg-aSYN-ABCC1-/- mice. Data is presented as means ± SEM (n = 6). 
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4.4.2 Quantification of aSYN upon ABCC1 knock-out using ELISA 
To quantify the aSYN level in the brain of 100 d old tg-aSYN-ABCC1-/- mice compared to 100 d 
old tg-aSYN mice, ELISA was performed with the carbonate fraction containing monomeric and 
small oligomeric aSYN and with the guanidine fraction containing non-soluble aSYN. 
Surprisingly, no significant differences were detected in either fraction comparing 
tg-aSYN-ABCC1-/- and tg-aSYN (ABCC1+/+) mice (see Figure 30). 
 
Figure 30: ELISA measurement of g-aSYN and tg-aSYN-ABCC1-/- mice. 
The carbonate fraction (A) revealed similar results compared with the guanidine fraction (B) in both examined mouse 
models. No significant changes were found. Data is presented as means ± SEM (n = 5). 
4.4.3 Influence of ABCC1 activation using thiethylperazine on neuron integrity 
and the immune response 
To validate a possible beneficial effect of ABCC1 activation on the pathology of tg-aSYN mice, 
thiethylperazine was administered. Tg-aSYN and tg-aSYN-ABCC1-/- mice were treated daily with 
thiethylperazine while untreated as well as water-treated mice served as control. 
Immunohistological analyzes were performed but unexpectedly, no visible changes were 
observed for thiethylperazine-treated compared to water-treated (control) mice (see Figure 31). 
The neuronal and the microglial area were quantified relative to the cortical area in a semi-
quantitative approach. Surprisingly, an increased neuronal area (~23 %) was found in water-
treated (control) mice when compared to untreated ones (p=0.0081). Thiethylperazine-treated 
tg-aSYN mice and tg-aSYN-ABCC1-/- mice displayed no changes compared to untreated mice (see 
Figure 32A). Similarly, the examination of microglial area revealed no significant difference upon 
treatment (see Figure 32B). 
Results 
67 
 
 
Figure 31: Immunohistochemical analyzes of thiethylperazine- and water-treated tg-aSYN mice. 
The panel shows a comparison between tg-aSYN mice either treated with thiethylperazine (left column; A,C,E) or 
water (right column; B,D,F). A differences was not visible when stained with NeuN (A,B) nor in case of Iba1 staining 
(C,D) or GFAP staining (E,F). Scale bar = 100 µm. 
 
Figure 32: Semi-quantitative analyzes of neuronal and microgial area in the cortex of tg-aSYN and tg-aSYN-
ABCC1-/- mice upon treatment with thiethlyperazine. 
The neuronal area per cortex area was unchanged in thiethylperazine-treated mice of both mouse models compared 
to untreated mice (A). Interestingly, neuronal area of water-treated (control) mice showed a significant increase of 
~23 % compared to untreated mice (A). The microglia area revealed no differences upon treatment (B). Data is 
presented as means ± SEM (n ≥ 5). (one-way ANOVA followed by Sidak’s multiple comparison test).  
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4.4.4 ABCC1 activation – quantification of aSYN by ELISA 
ELISA measurements were performed to investigate the influence of ABCC1 activity on the 
concentration of aSYN in the brain of tg-aSYN mice. A decrease in aSYN burden was excluded by 
the present results. Monomeric (carbonate-soluble) aSYN increased significantly upon 
thiethylperazine-treatment in tg-aSYN mice (42 %; p=0.0406; Figure 33A). By trend, also an 
increase in water-treated (control) mice was found (p=0.0782; see Figure 33A). As no significant 
difference was detected between thiethylperazine-treated tg-aSYN and tg-aSYN-ABCC1-/- mice, a 
causal ABCC1-dependent mechanism could be excluded. The decrease of aggregated aSYN in the 
guanidine-soluble fraction upon thiethylperazine- and water-treatment was not significant (see 
Figure 33B).  
 
Figure 33: ELISA measurement of tg-aSYN and tg-aSYN-ABCC1-/- mice upon treatment with thiethylperazine in 
contrast to untreated and water-treated mice. 
Pharmacological activation of ABCC1 had no impact on the concentration of monomeric (carbonate-soluble) aSYN (A) 
or aggregated (guanidine-soluble) aSYN (B) in the brain of 100 d old tg-aSYN mice when compared to water-treated 
(control) mice. Interestingly, thiethylperazine increased the proportion of monomeric aSYN significantly in 
thiethylperazine-treated tg-aSYN compared to untreated mice (A), whereas guanidine-soluble aSYN showed no 
difference (B). Data is presented as means ± SEM (n ≥ 5). (one-way ANOVA followed by Sidak’s multiple comparison 
test). 
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5. Discussion 
Until today, the underlying cellular mechanisms leading to the abnormal aSYN expression and 
the resulting cell fate culminating in the characteristic symptoms of synucleopathies are still not 
fully understood. It is well accepted that the overexpression and deposition of aSYN causes the 
onset of PD. Starting with the accumulation of soluble monomers, aSYN accumulates into 
oligomers and further on into fibrils and deposits into the characteristic Lewy bodies and Lewy 
neurits. Besides age, genetic predisposition is a known risk factor for PD, but most often disease 
onset occurs sporadically without known cause. In the past, research has been focused on 
finding triggers of PD. Here, especially the recognition of pesticides like MPTP and rotenone led 
to new insights into PD pathogenesis (Moore et al., 2005). With the comprehension of the 
mitochondrial damage caused by these pesticides, a new field of research emerged and 
promoted a different view on PD.  
The present study aimed to characterize the well-known and widely used tg-aSYN mouse model 
with ‘A30P’ mutation, of which several contradictory results exist, and to investigate whether it 
is a proper model to mimic PD. Furthermore, the influence of mitochondrial polymorphism on 
the pathology in the tg-aSYN mouse model was of interest. Scheffler et al. determined certain 
mitochondrial polymorphisms in the context of Alzheimer’s disease and found an increased 
production of ATP (Scheffler et al., 2012). Inspired by this study, the respirometric analysis of 
isolated brain mitochondria in the present work extended these previous findings. It was 
additionally possible to find a conceivable explanation for the increased ATP production that 
was accompanied by improved motor performances and neuronal integrity found in this inbred 
mouse strain when compared to the common tg-aSYN mouse. The altered mitochondrial 
respiration in the aSYN overexpressing PD mouse model and the results found determining the 
tg-aSYN mouse model with mitochondrial polymorphisms led to the investigation whether the 
ATP-dependent ABC transporter activity/ function might be crucial to PD pathology and would 
be found beneficial to be improved pharmacologically.  
5.1 The tg-aSYN mice is a convenient model for synucleopathies 
Mouse models are widely used to model PD in research because of their human-like 
neurochemistry. Depending on the promoter and overexpressed protein, the known transgenic 
PD mouse models display different features of the disease. Mostly they are created on the basis 
of familial PD, using the overexpression of mutated aSYN to mimic the disease. Many models 
were generated in the past decade and described detailed; however, their relevance for PD 
research has been extensively discussed (Chesselet, 2008). 
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The, in the present study used, tg-aSYN mice overexpresses the ‘A30P’ mutated aSYN under the 
Thy1 promoter and were described different by diverse groups concerning phenotypic 
alteration, behavior and histology. In order to further investigate these mice in the context of PD 
and synucleopathies, their characteristics were re-evaluated focusing on parameters that were 
of interest for the further experiments.  
The Thy1 promoter ensures a broad expression in neurons throughout the brain, cortical as well 
as subcortical and, still discussed, in the SNpc (Masliah et al., 2000).  
While some groups were not able to find aSYN expression in the SNpc (Neumann et al., 2002; 
van der Putten et al., 2000), Rockenstein and coworkers observed aSYN accumulation in this 
structure of the brain (Rockenstein et al., 2002). Interestingly, using this promoter, no 
pathological glial, spinal or neuromuscular alterations were found (Rockenstein et al., 2002). 
Furthermore, aSYN was found to accumulate in basal ganglia and thalamus but not in the spinal 
cord or neuromuscular junctions leading to the assumption that this mouse models properly 
mimics characteristics of PD (Rockenstein et al., 2002). However, Van der Putten et al. 
acknowledged the presence of aSYN depositions in neuromuscular junctions and also found 
motor neuron degeneration and concluded additional DLB (dementia with Lewy bodies) aspects 
(van der Putten et al., 2000). An aSYN expression in cell bodies of pyramidal neurons in cortex 
and limbic system was described in agreement (Rockenstein et al., 2002; van der Putten et al., 
2000). 
In the present work, a broad aSYN expression throughout various brain structures was 
approved histologically, including cortex, thalamus, hippocampus, basolateral amygdala, 
geniculate nucleus, zona incerta and the pyramidal neurons, which were stained most 
intensively. Other parts of the brain only displayed mild aSYN expression, like hypothalamus, 
medial amygdala and dentate gyrus. However, no aSYN expression was found in SNpc and 
olfactory bulb, two structures with prominent expression in post mortem brain tissue of PD 
patients. This gap between human disease and current mouse models has been described 
previously (Freichel et al., 2007). 
In contrast to Kovacs et al., who developed and used the IgG1 κ isotype monoclonal antibody 
(5G4) to stain brain sections of human PD patients (Kovacs et al., 2012), it was possible to find 
the synapses and somata in the cerebral neurons of mice to be strongly labelled, reflecting the 
overexpression of aSYN in the mouse model, similar to previous reports (Rockenstein et al., 
2002; van der Putten et al., 2000). Kovacs and colleagues described a weak and diffuse reactivity 
of the antibody with monomeric aSYN when determined by Western Blot but a much higher 
binding affinity to aggregates (Kovacs et al., 2012). However, the absence of these aggregates 
(Lewy body or Lewy neurit pathology) in the mouse brain (Meredith et al., 2008) favored the 
widespread binding to small oligomers, which are enriched in synapses and somata due to the 
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artificial overexpression of human aSYN. This possibly explains the diffuse staining pattern seen 
in histology with a strong background signal in various structures of the brain. 
Intense aSYN expression was observed in the cortical layer V as well as layer II/III. Here, the 
small and large pyramidal neurons originate which innervate for example the basal ganglia. In 
the hippocampus, the CA1 and CA3 region were stained most intensively by the anti-aSYN 
antibody whereas the CA2 region lacked reactivity. Interestingly, both stained regions are 
pyramidal cell fields, innervated by the entorhinal cortex and highly involved in learning and 
memory. Both brain structures are highly important in the pathology of PD, as they are involved 
in movement and cognition (Witter et al., 2014). The finding that, contrary to the human 
situation, the SNpc is not involved in the pathology of the transgenic mouse models challenged 
the current view. A model that does not display one of the most prominent hallmarks of PD, the 
SNpc pathology, has to be regarded with caution.  
Additionally, there are other promoters with different features that are widely used to mimic PD 
in animal models. For example, the tyrosine hydroxylase promoter is restricted to 
catecholaminergic neurons and leads to a nigrostriatal pathology. However, different studies 
revealed that either at least double mutated or truncated aSYN is essential to induce damage 
(Thiruchelvam et al., 2004; Tofaris et al., 2006). Additionally, neuronal loss occurs early in these 
mice but does not progress properly and do not include other brain structures. A broad 
expression in neurons of different structures such as neocortex, limbic system and olfactory 
regions is enabled by the PDGF-beta (platelet-derived growth factor) promoter (Chesselet, 
2008). aSYN expression in glial cells triggered a pathology similar to features of multiple system 
atrophy rather than PD (Rockenstein et al., 2002). Masliah et al. found that these mice develop 
motor deficits by the age of 12 month, display dopaminergic cell loss and build up inclusion 
bodies (Masliah et al., 2000). Nonetheless, the expression of aSYN under the Thy1 promoter is 
several folds higher than under the PDGF promoter (Rockenstein et al., 2002).  
The neuronal expression of aSYN in the brain of tg-aSYN mice was fully developed as early as 
from 50 d of age and was histologically indistinguishable from of the expression at 300 d. The 
postnatal expression of aSYN under the Thy1 promoter increases exponentially in the first 
weeks of age (Moechars et al., 1999). At the age of 50 d, fewer aSYN positive and degenerated 
neurons in the enlarged cortex sections were found than at the age of 300 d, suggesting a less 
progressed pathology. Relative quantification of the cortical neuronal area revealed significant 
differences between tg-aSYN mice and C57BL/6J control mice. Despite the missing LB patholohy, 
tg-aSYN mice had an about 35 % reduced neuronal area in the cortex compared to control mice.  
A possible explanation for this phenomenon is the probably ongoing removal of aSYN from the 
brain, which leads to an equilibrium between production and removal and thus, to the observed 
steady state of aSYN burden (in form of oligomers) in the brain of young and old tg-aSYN mice. 
However, the prominent neuronal cell loss indicates that small monomers and oligomeric forms 
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of aSYN are more toxic than the aggregated form (Lewy bodies in human brains). These findings 
confirm the role of aSYN in the pathology of PD. Although it is possible to correlate the number 
of LBs in a certain structure (e.g. SNpc) with the severity of local pathology in PD patients (Braak 
et al., 2003), dying neurons do not necessarily contain LBs and especially dopaminergic neurons 
containing LBs do not undergo apoptosis to a greater extent than other cells (Schulz-Schaeffer, 
2010). In conclusion, the overall disease progress does not correlate well with the formation of 
LBs and thus, they might be only an epiphenomenon to other still unknown mechanisms 
(Bellucci et al., 2012). Interestingly, it was found that aSYN is able to spread like prions in an 
infective way and it was demonstrated that extracellular aSYN oligomers can introduce 
intracellular aSYN aggregation (Kovacs et al., 2014; Danzer et al., 2009). The previously 
described “dying back” hypothesis further supports these observations. aSYN, located mainly in 
presynaptic terminals, leads to synaptic dysfunction by oligomerization, when the normal 
binding of aSYN to synaptic vesicles as part of the SNARE-complex is disturbed (Burre et al., 
2010). Recently, Burré et al. showed that the ‘A30P’ mutation is unique among the aSYN point 
mutations in impairing SNARE-complex formation (Burre et al., 2012). As a consequence the 
disturbed synaptic maintenance leads to disrupted neuronal activity culminating in its death. 
This phenomenon was already observed in DLB with the notion that 90 % of all aSYN aggregates 
were found in the presynapses (Schulz-Schaeffer, 2010). Thus, the question arises whether LBs 
are, in fact, not the crucial part of PD pathology, which would also explain the PD phenotype in 
mice without LB formation. Once more, these findings support the concept that monomeric and 
small oligomeric aSYN are the toxic species in PD and DLB. 
Two behavioral tests, the rotarod and the pole test, were performed in order to assess possible 
motor alterations in tg-aSYN mice, similar to the progressive motor disease PD. Previous 
descriptions of age-dependent movement abnormalities in homozygous tg-aSYN mice included 
an unsteady gait, a weakening in the limbs and an abnormal tail posture within the first year of 
life (Neumann et al., 2002). The in the present work used heterozygous mice displayed motor 
abnormalities starting at 300 d of age and interestingly a large proportion of old mice 
additionally featured severe eye defects in form of blindness in one eye (Gröger, 2012, Master 
thesis). Before reaching old age, their physiological appearance did not differ except for a 
tendency to lower weight in the first few months as determined in this work. Furthermore, 
Freichel and colleagues found old tg-aSYN mice to perform significantly worse in fear 
conditioning and active avoidance test, both requiring the involvement of amygdala and 
hippocampus. They also described a worsening in the rotarod performance but starting not 
earlier than 12 month of age (Freichel et al., 2007). A preliminary study previously performed in 
our lab revealed no significant differences in the rotarod performance until 450 days of age, but 
with a rapid decline after reaching this old age. A difference between young and old tg-aSYN 
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mice was visible from 300 d of age, similar to findings made by Freichel et al. (Gröger, 2012, 
Master thesis; Freichel et al., 2007).  
In this study, the main interest lay on earlier time points in order to make out early differences 
and rotarod was performed starting at 9 weeks of age and was finished by the age of 41 weeks. 
No differences were found between tg-aSYN and control mice concerning the time mice were 
able to stay on the rotating rod and for the time they firstly accomplished a passive rotation, 
without actively walking on the rod. An exceptional slipping of the rod as described by Tabuse et 
al. did not occur (Tabuse et al., 2010). These results confirmed the above mentioned findings 
made by Freichel and colleagues. Interestingly, statistical analyzes of the performances revealed 
a positive increase of performance with advancing age in both parameters. Mid-age tg-aSYN 
mice were found to tend to hyperactivity and concomitant with that to show increased swim 
speed in the morris water maze test (Freichel et al., 2007), that phenomenon might explain the 
missing differences in motor performance tests and underline the results described in the 
present work.  
A second test, the pole test, described as suitable for basal-ganglia related movement disorders 
(Fleming et al., 2004) was performed again from 9 to 41 weeks of age. Although no difference 
was found concerning the orientation task, unexpectedly the climbing performance was 
performed significantly worse in case of control mice when compared to tg-aSYN mice, matching 
the described observations made by Freichel et al. (Freichel et al., 2007).  
The rotarod and pole test are methods to examine coordinated motor skills and are widely used 
to detect nigrostriatal damage and dopaminergic denervation (Fernagut et al., 2003; Matsuura et 
al., 1997; Fleming et al., 2004). The missing difference between tg-aSYN mice and the C57BL/6J 
(control) mice is likely founded in the lack of SNpc pathology due to the expression pattern of 
the Thy1 promoter, described before (Neumann et al., 2002; van der Putten et al., 2000).  
In sum, an impairment of motor coordination and performance was found in heterozygous 
tg-aSYN mice compared to non-transgenic control mice at the age of 9 to 41 weeks. Furthermore 
it was not possible to determine phenotypical changes regarding tg-aSYN mice in the respect 
age. With these findings, the present work fits well into already published results regarding the 
used tg-aSYN mouse model (Freichel et al., 2007). With respect to our question whether this 
mouse model is suitable to study PD, the answer is ambiguous. While it is not suitable to model 
PD as motor disease, the robust expression of mutated aSYN throughout the brain allows 
investigation of dementia (concomitant with PD) and extranigral aspects of the disease as well 
as degeneration of neurons. It furthermore was found to feature different characteristics of DLB 
or a pre-manifested form of PD (Schell et al., 2009; Freichel et al., 2007; Meredith et al., 2008) 
and can be generally denoted as model for α-synucleopathies.  
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5.2 Beneficial effects of mitochondrial polymorphisms on aSYN 
pathology in tg-aSYN mice 
Mitochondrial dysfunction is one of the major hypotheses described today to be causative for 
PD. It is widely acknowledged that during age, mutations in the mitochondrial genome (mtDNA) 
accumulate followed by an excessive production of reactive oxygen species (ROS). A knock-in 
mouse model with a mutated mtDNA-polymerase A brought first evidence for the assumption of 
mitochondrial dysfunction being implicated in aging (Larsson, 2010).Here a deficiency in the 
proof-reading function of the protein was described leading to a decreased lifespan and early 
onset of age-related phenotypes (Trifunovic et al., 2004). In addition, complex I-deficiency was 
discovered in the SNpc of PD patients, adding evidence to the hypothesis (Martin, 2012; 
Schapira, 2006). 
For the investigation of mitochondrial influences on the aSYN pathology of tg-aSYN mice, a novel 
conplastic mouse strain was generated, the tg-aSYN-mtNOD mice. The mitochondrial genome for 
the novel mouse model was provided by the well-known none-obese diabetic (NOD/LtJ) mouse, 
a model used for autoimmune diabetes (Leiter, 2001). This model was sequenced previously and 
distinct differences were found in the mitochondrial genome (Yu et al., 2009). Table 19 resumes 
the important polymorphisms.  
Table 19: Mitochondria gene differences between NOD/LtJ and C57BL/6J mice.  
(adopted from (Yu et al., 2009)) 
gene mtDNA position C57BL/6J NOD/LtJ amino acids 
Cox3 9348 bp G A Val > Ile 
ND3 9461 bp C T Met > Met 
tRNAArg 9821 bp 8A repeats 10A repeats  
 
In the present report, these two tg-aSYN mouse strains with mitochondrial genome differences 
expressing human aSYN with ‘A30P’ mutation were analyzed regarding aSYN load, immune 
response, neuron integrity, and behavioral changes with the focus on differences due to the 
mitochondrial polymorphisms.  
Starting with the immunohistochemical analyzes of tg-aSYN-mtNOD mice, only small differences 
were found compared to tg-aSYN mice. However, the differences were not as distinct as to make 
definite statements. It obviously can be ruled out that the mtNOD genome has influence on the 
production of aSYN under the Thy1 promoter. To be sure, ELISA was performed. Differences 
were only found examining aggregated/ fibrillar forms, as here an increase in 300 d old 
tg-aSYN-mtNOD mice was visible compared to tg-aSYN mice. These findings emphasize the 
supposition of the higher molecular forms of aSYN to be less toxic than the smaller soluble 
monomeric moieties, and the aggregation to be a mechanism protecting neurons from further 
damage, as already described above (5.1). These observations fit into this theory and also get 
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well along with proposals made by several other research groups in the context of different 
neurodegenerative diseases (Zhang et al., 2014; Conway et al., 2000; Assayag et al., 2007). 
Recently, Zhang and colleagues found a transgenic AD-mouse model to show AD progression 
without the development of a single plaque but with Aβ oligomer accumulation in the neurons 
(Zhang et al., 2014). This notion in the context of AD was already described before (Walsh et al., 
2007); similarly, in PD research Conway et al. suggested that the aSYN oligomer formation is 
critical for pathogenesis rather than fibrillization (Conway et al., 2000). Additional evidence is 
brought by the findings of post mortem brains of non-PD cases containing LBs (Gibb et al., 1988). 
However, the aggregation as mechanism of protection to neurons seemed to be enhanced in 
tg-aSYN-mtNOD mice. Still, possible reasons are unknown.  
Concomitant with these findings, the neuronal integrity in old age was highly disturbed in 
transgenic mice and also in old control mice as compared to young ones, indicating that the 
degeneration process is part of the normal aging. For tg-aSYN mice these observations were 
already described in 5.1. Intriguingly, determining the proportion of neuronal area in the cortex 
of tg-aSYN-mtNOD mice revealed that the neuronal integrity is completely rescued in 300 d old 
mice when compared to tg-aSYN mice. One possible explanation is that an impairment of the 
aSYN functionality as modulator of synaptic activity is missing due to the absence of the 
pathological aggregation behavior of aSYN leading to less dying neurons. 
It was furthermore possible to detect a significantly increased immune response by microglia in 
300 d old tg-aSYN-mtNOD mice when compared to control mice. An increased microglial 
response is one of the histological characteristics of PD in humans and known to correlate with 
aSYN burden in the brain (Russo et al., 2014). Microglia are immune cells of the central nervous 
system, capable of phagocytosis and the secretion of proinflammatory cytokines. Their 
contribution to disease development is discussed controversially (McGeer et al., 2008). It was 
described that microglia undergo a phenotypical change when activated chronically. 
Additionally, they change their secretion of proteins, which they use to increase adhesion and 
migration, phagocytosis and to stimulate neighboring cells (Olah et al., 2011). Chronic 
inflammation is a pathological hallmark of different neurodegenerative diseases and increased 
microglia activity might be detrimental for neurons due to a chronic expression of neurotoxic 
factors. Chronic microglial activation leads to enhanced Aβ production in AD (Rojo et al., 2008; 
Azizi et al., 2012). The SNpc was found to host particularly high amounts of microglia (Lawson et 
al., 1990). Notably, aSYN has a regulatory influence on the phenotypic alterations of microglia, as 
an increased reactive phenotype was found in aSYN knock-out mice compared to control. 
Furthermore, these microglia secreted elevated level of proinflammatory cytokines TNFα and 
IL-6, and displayed an impaired ability for phagocytosis compared to microglia from non-
transgenic control mice (Austin et al., 2006). A preferred theory today is that microglia have a 
variety of different activation states and corresponding phenotypes (Gordon, 2003). The 
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microglia found in the brains of aSYN knock-out mice revealed a ramified, vacuolar morphology 
(Austin et al., 2006). The activation state of the microglia in this work is unknown. However, as 
neuronal integrity was completely intact in old tg-aSYN-mtNOD mice, the found increased 
microglial response in old tg-aSYN-mtNOD mice is in contrast with the discussed detrimental 
effect of microglial activity. These findings support the controversially debated hypothesis of a 
neuroprotective effect emanating from microglia (Hellwig et al., 2013). An enhanced microglial 
presence was also found by Scheffler et al. in the vicinity of Aβ plaques in an mtNOD-mouse 
model of AD accompanied by a decreased level of cerebral Aβ load and higher uptake levels in 
microglia when compared to C57BL/6J controls. Moreover, a higher ATP level was described for 
the respective mouse model, which is according to the authors the reason for the increased 
microglial activity and important for the brain homeostasis (Scheffler et al., 2012).  
To verify that the described changes found in tg-aSYN-mtNOD mice were not only histological 
phenomena but had indeed a beneficial impact on motor skills, behavioral tests were performed 
and evaluated as described before. The rotarod test proved a great advantage of the 
tg-aSYN-mtNOD in mid-age time points (25-33 weeks) elicited by their mitochondrial 
polymorphisms and confirmed thereby formerly described results. The on the one hand strong 
difference between tg-aSYN and tg-aSYN-mtNOD mice in the rotarod performance but missing 
variance in the climb performance of the pole test could be explained by the less phenotypic 
alteration in the transgenic mice. The very sensitive pole test (Fernagut et al., 2003) was most 
likely not suitable for extranigral aspect determination and stronger incentives for the mice 
were needed for future analyses. However, the ability of spatial orientation, a non-motor task, as 
part of the pole test was disturbed in old tg-aSYN and control mice and increased in tg-aSYN-
mtNOD mice. Thus, a strong positive effect on the motor performance and spatial orientation 
task was found in tg-aSYN-mtNOD mice, confirming the results of the rotarod test. 
In conclusion, the newly created tg-aSYN-mtNOD mice was found to feature great benefits with 
respect to neuronal integrity, microglial response, motor performance and spatial orientation 
compared to tg-aSYN mice without mitochondrial polymorphisms, especially in old age. These 
results add new evidence to the hypothesis that mitochondria have a great impact on the 
pathophysiological coherences in the PD brain.  
5.3  Respirometric measurements revealed mtDNA specific differences 
in oxygen consumption of isolated brain mitochondria 
In order to find an explanation for the beneficial effects found in tg-aSYN-mtNOD mice compared 
to tg-aSYN mice, the function was investigated in isolated brain mitochondria and evaluated by 
means of high-resolution respirometry with substrate inhibitor titrations (Kuznetsov et al., 
2008; Kupsch et al., 2014). A set of four protocols (Trumbeckaite et al., 2001; Gellerich et al., 
2002; Gellerich et al., 2008; Gellerich et al., 2012; Krebiehl et al., 2010) allowed obtaining a 
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maximum of information based on the determination of the maximal substrate specific state 3-
respiration, also upon Ca2+ stimulation, maximal rates limited by the capacity of the respiratory 
chain complexes, respiratory control ratios and non-phosphorylating states of respiration (state 
4).  
Starting with the evaluation of complex I-dependent respiration rates, a difference was solely 
found in state 3-respiration in young mtNOD mice when α-ketoglutarate/malate as starting 
substrate was used and only after maximal stimulation with Ca2+. The ability of 
intramitochondrial Ca2+ to regulate oxidative phosphorylation via the activation of the 
pyruvate-, isocitrate- and α-ketoglutarat dehydrogenase leading to pyruvate formation through 
the tricarboxylic acid cycle, is known and widely accepted knowledge (McCormack et al., 1979; 
McCormack et al., 1993). However, this was considered not sufficient to explain increased 
oxidative phosphorylation by Ca2+ in vivo since these mechanisms only enhance the oxidation of 
the substrates (Gellerich et al., 2010). Recently, it was described that 
extramitochondrial/cytosolic Ca2+ increases the activity of aralar (mitochondrial 
aspartate/glutamate carrier, AGC) as part of the malate/aspartate shuttle (MAS) leading to 
increased regeneration of NAD+ to NADH+H+ and an increased substrate transport into the 
mitochondria. The required Ca2+ concentration is small and do not lead to Ca2+ uptake into the 
mitochondria (Pardo et al., 2006). Recently, Gellerich et al. described that 
extramitochondrial/cytosolic Ca2+ increases state 3-respiration most when glutamate/malate is 
provided as substrate, followed by α-ketoglutarate/malate while the presence of 
pyruvate/malate only display low stimulatory effect upon Ca2+ supply. Together, both 
mechanisms, intramitochondrial dehydrogenases and MAS activation, are believed to lead to an 
increase in substrate supply into the mitochondria and an enhanced formation of pyruvate 
(Gellerich et al., 2012). The addition of pyruvate after Ca2+ stimulation led to a further increase 
in respiration in the present work (Figure 20A), explainable by the up-regulating effect of 
cytosolic Ca2+ on pyruvate formation rather than an influence on the capacity to oxidize 
pyruvate. Gellerich et al. furthermore describe that the increased state 3-respiration in the 
presence of α-ketoglutarate/malate depend on the activation of intramitochondrial α-
ketoglutarate dehydrogenase and not on the activation of MAS. However, due to inconsistent 
findings upon inhibition of Ca2+ uptake into the mitochondria, further investigation is required. 
They conclude that Ca2+ controlled activation is realized by aralar using 
extramitochondrial/cytosolic Ca2+ and the intramitochondrial dehydrogenases utilizing 
intramitochondrial Ca2+. Nonetheless, high extramitochondrial/ cytosolic Ca2+ concentration led 
to an intake of Ca2+ into the mitochondria and was found to activate intramitochondrial 
dehydrogenases (Gellerich et al., 2012).  
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Figure 34: Cytosolic Ca2+-regulation of Malate-aspartate NADH shuttle (MAS) and intramitochondrial Ca2+ 
stimulation of dehydrogenases control mitochondrial pyruvate supply (Satrustegui et al., 2007). 
MAS consists of four enzymes: (1) mitochondrial and cytosolic aspartate aminotransferase (AAT), (2) malate 
dehydrogenases, the α-ketoglutarate/malate carrier (OGC) and the aspartate/glutamate carrier (aralar, AGC), which is 
activated by cytosolic Ca2+. Ca2+ transported into the mitochondria via the Ca2+ uniporter (CU) activates (3) pyruvate 
dehydrogenase, (4) isocitrate dehydrogenase (IDH) and (5) α-ketoglutarate dehydrogenase (α-KGDH). AcCoA, acetyl 
CoA; Asp, aspartate; Glut, glutamate; Isoc, isocitrate; α-KG, α-ketoglutarate; Mal, malate; OAA, oxalacetic acid; Pyr, 
pyruvate; SuccCoA, succinil CoA (Satrustegui et al., 2007). 
In the present work, an additional supply of Ca2+ led to a greater increase in state 3-respiration 
measured with glutamate/malate as compared to α-ketoglutarate/malate, confirming the 
hypothesis described by Gellerich et al. (2012). The observed difference between young 
C57BL/6J and mtNOD mice might thus depend on alterations in the activation of the 
α-ketoglutarate dehydrogenase activity by intramitochondrial Ca2+ but other coherences might 
play an important role and should be further investigated. 
It was possible to find the greatest differences in complex II-dependent parameter of 
mitochondrial function. The succinate-dependent state 3-respiration was diminished about 
20 % in 200 d old C57BL/6J (Control) mice compared to mtNOD mice of the same age. As a 
consequence the complex I/complex II-ratio was also increased by 15 % in old Control mice. 
These differences were obtained by using glutamate/malate as starting substrate, 
α-ketoglutarate/malate did not led to differences unless further stimulation by 
glycerol-3-phosphate and was generally smaller compared to glutamate/malate. Furthermore, 
the non-phosphorylating respiration (state 4) revealed also significantly lower 
complex II-dependent respiration rates in brain mitochondria from 200 d old C57BL/6J mice 
compared to mtNOD mice. In contrast, complex I-limited rates of state 4-respiration were not 
changed (4.3.6, Figure 27). The basal oxygen consumption without or with low ADP (state 4), 
leading to a high ADP/ATP ratio, indicates, if increased, a proton leak across the membrane 
probably induced in isolation procedure (Horton et al., 1981). Even if the state 4-respiration of 
200 d old mtNOD seems increased in contrast to 200 d old C57BL/6J mice, it is more likely a 
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diminished state 4-respiration in case of C57BL/6J mice versus 100 d ones while the 200 d old 
mtNOD mice display unchanged state 4-respiration rates.  
The, from the respective state 3 and state 4 calculated, respiratory control ratio (RCR) confirmed 
the findings. The complex I-dependent RCR displayed no differences while complex II-dependent 
RCR was increased in 200 d old C57BL/6J mice compared to 100 d old ones. The RCR is a 
dimension for coupling of ETC and oxidative phosphorylation and quantifies a possible leak in 
the inner mitochondrial membrane (Horton et al., 1981). Here, the increased RCR in case of 
complex II-dependent respiration for 200 d old C57BL/6J mice is caused by the simultaneously 
diminished state 4-respiration. Membrane integrity is intact as proofed by the unchanged RCR 
for complex I-dependent respiration.  
Explanation for these repeated findings of diminished succinate respiration in C57BL/6J mice 
might be a metabolic condition. The activity of succinate dehydrogenase (SDH) is known to 
depend on the concentration of oxaloacetate and malate, both inhibitors of SDH. The 
mitochondrial aspartate amino-transaminase (ASAT) catalyzes the reaction of glutamate and 
oxaloacetate to α-ketoglutarate and aspartate; either decreasing the oxaloacetate concentration 
if reacting with glutamate or vice versa if reacting with α-ketoglutarate (Panov et al., 2009). 
However, this explains the finding of a lower succinate respiration measured with α-
ketoglutarate compared to glutamate (4.3.2, Figure 21). The presence of α-ketoglutarate leads to 
an increasing oxaloacetate concentration partially inhibiting the SDH, while using glutamate as 
substrate leads to lowest oxaloacetate concentration not inhibiting the SDH. But the finding of 
reduced succinate respiration rate upon glutamate in old C57BL/6J mice cannot be explained by 
this principle (4.3.2, Figure 21), as it cannot be caused by an increased oxaloacetate 
concentration. Thus, a diminished activity of SDH or the electron-transferring flavoprotein-
ubichinone oxidoreductase (ETF), possibly caused by increased oxidative stress could be a 
possible reason. 
Although succinate is not an important substrate for feeding the brain’s mitochondria, 
complex II is a crucial enzyme for mitochondrial respiration and has a pivotal role in the citrate 
cycle by limiting the supply of reducing equivalents to the respiratory chain. This complex 
differs from the others as it comprises of four subunits and its genes are all nuclear-encoded 
(Quinlan et al., 2012). Mitochondrial diseases which are associated with deficiency in complex II 
lead to severe neurological phenotypes, such as encephalopathy, mostly together with a very 
short life span. These rare deficiencies in SDH were described by Alston et al. to lead to motor 
manifestations in two children with novel variants in SDH genes and probably to altered binding 
and procession of electrons in the respiratory chain (Alston et al., 2012). A connection between 
SDH defects and tumourigenesis, i.e. angiogenesis, was also made before when succinate, among 
other citrate cycle intermediates, was found to influence the availability of hypoxia-inducible 
transcriptions factors (HIFs) and act as tumour suppressor (Koivunen et al., 2007). The HIFs 
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play also an important role in other physiological and pathological issues, for example in cell 
proliferation, apoptosis and glucose utilization (Koivunen et al., 2007). A decrease in complex II-
dependent respiration as found in old C57BL/6J mice might not lead to the severe phenotypic 
alterations as described in patients with SDH gene mutations, but a noxious impact on 
metabolism is likely to occur with increasing age. However, this unknown metabolical impact 
emerging with ongoing age and triggered by a decreased complex II-dependent respiration, 
either affecting SDH or ETF, is apparently bypassed in mice with NOD polymorphisms. 
After missing differences in complex III-dependent respiration, complex IV-dependent 
respiration revealed interesting results. While the respiration rate in both mouse strains, 
C57BL/6J and mtNOD mice, drops in the same extend with advancing age when measured with 
glutamate/malate as starting substrate, is this drop greater in mtNOD mice upon measurement 
with malate/α-ketoglutarate. This finding depends on the increased respiration rate in 100 d old 
mtNOD mice, which cannot be found when measured with glutamate/malate. A decreased 
complex IV activity was described before for mtNOD mice depending on the polymorphism in 
Cox3 (5.2, Table 19) (Scheffler et al., 2012). However, a significant difference between C57BL/6J 
and mtNOD mice is missing. Furthermore, COX activity does not reach limit when supplied with 
saturating ADP and substrate but can be further stimulated to a maximum, also referred to as 
‘excess capacity’ of COX (Gnaiger et al., 1998). Thus, changes in complex IV-activity do not lead to 
effects on electron flux through the respiratory chain probably providing a safe range in case of 
mtDNA mutations as was found in different tissues and species (Letellier et al., 1994; Gnaiger et 
al., 1998). The minor results of the complex IV-dependent respiration in the present work have 
therefore certainly no impact on energy metabolism of brain mitochondria. Additonally, Gnaiger 
et al. proposed an economic ideal behind the excess capacity of COX by up-regulating the oxygen 
affinity, ensuring a “thermodynamic and kinetic optimum” upon maximal flux through the 
respiratory chain (Gnaiger et al., 1998). The excess capacity was calculated as quotient of the 
complex IV-dependent respiration and the maximal ETC capacity upon uncoupling with FCCP. 
FCCP destroys the proton gradient across the inner membrane by forming a pore and serving as 
proton carrier integrated into the inner mitochondrial membrane. As a consequence, electron 
flux becomes maximally increased trying to compensate for the leak and to ensure maintenance 
of a proton gradient. The control of the ATP-synthase has no longer influence on the flux (Pesta 
et al., 2012). The maximal ETC capacity after FCCP addition revealed no differences between age 
and strain. The, normalized to these results calculated, COX excess capacity revealed no 
differences, too and ranged between 1-1.3-fold (Figure 25). Thus, the mtNOD polymorphisms 
had no effect on maximal electron flux through the respiratory chain and did not change the 
activity of complex IV and the corresponding excess capacity. 
Taken together, the in the present work examined mitochondrial polymorphisms reveal most 
vigorous differences in the respiration capacity of complex II of the respiratory chain.  
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It would be of utmost interest to perform respirometry also with transgenic mice to determine 
the additional influence of the overexpressed aSYN on the oxygen consumption of various 
complexes. The in the present work by respirometry achieved results are limited in the outright 
transferability on the findings made with the transgenic aSYN-mice. Nonetheless, it is possible to 
see connections between the described improved results in tg-aSYN-mtNOD mice compared to 
tg-aSYN mice and the found enhanced complex II-dependent respiration in the mtNOD 
background strain.  
Thinkable is that the enhanced complex II-activity might compensate for the 
complex I-deficiency associated with PD leading to an equation in energy metabolism in 
tg-aSYN-mtNOD mice, which would explain the found improvements in neuron integrity, motor 
performance and spatial orientation. Evidence for this assumption was found in mice with MPTP 
induced parkinsonism, as it was shown that the complex I deficiency was bypassed by a 
complex II-dependend mechanism induced by an infusion of the ketone body d-beta-
hydroxybutyrate, leading to improved mitochondrial respiration and ATP production (Tieu et 
al., 2003). 
An enhanced complex II-activity could also result in diminished ROS production, as it was shown 
that complex II can generate ROS in rates which exceed those of complex I and III, under certain 
circumstances (Quinlan et al., 2012). Recently it was described that complex II also influences 
the ROS production in human skin mitochondria and that aging leads to a decreased enzyme 
activity (Anderson et al., 2014). 
Scheffler et al. found transgenic AD mice with mtNOD polymorphisms to have a significantly 
greater cellular ATP level and microglia activity concomitant with decreased Aβ burden in the 
brain (Scheffler et al., 2012). ATP-dependent mechanisms that support the cell in the clearance 
of toxic peptides such as UPS might be increasingly activated in this mouse model. Consequences 
of a dysfunctional UPS were shown in parkin knock-out mice, resulting in a loss of function in 
dopaminergic neurons and in a decrease in mitochondrial respiration leading to a further 
decreased ATP level (Martin, 2012). Additonally, the insulin-degrading enzyme and neprilysin, 
proteases, are affected by inconsistent ATP level. Their contribution to PD, however, lacks still 
confirmation (Song et al., 2004). An important mechanism for peptide removal is furthermore 
the active transport across the BBB by ABC transporters, as these are highly energy-dependent.  
This interesting phenomenon cannot be explained in fully detail today but unquestionable these 
results confirm the importance of the mitochondria-neurodegeneration network. 
5.4  ABCC1 activity is not crucial for aSYN transport in the brain of 
tg-aSYN mice 
The BBB (blood brain barrier) and the BCB (blood cerebrospinal fluid barrier) are important for 
the protection of the brain against harmful and toxic compounds from the blood. Exchange 
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across these barriers is tightly regulated. The active bi-directional transport is carried out by 
specific transport molecules located within the endothelial cell layer. Together with the 
surrounding pericytes and astrocytes’ endfeet, these endothelial cells form the BBB. In contrast 
to the BCB, the BBB provides a specialized diffusion barrier build by tight junctions ensuring a 
certain homeostasis in the brain (Pahnke et al., 2009; Zlokovic, 2008; Loscher et al., 2005).  
ABC transporters represent a large family of transport molecules present at the BBB, which 
recently gained great interest for their involvement in neurodegeneration. The ABC transporter 
ABCB1 (P-gp, P-glycoprotein 1; MDR1, multidrug resistance protein 1) was already intensively 
investigated for its implication in PD. Its activity was diminished in brain regions that are 
prominent in disease development, for example frontal regions with frontostriatal neuronal 
projections (Bartels et al., 2009; Bartels et al., 2008b; Kortekaas et al., 2005). The role of another 
important ABC transporter ABCC1 (MRP, multidrug resistance-associated protein 1; refer to 
Figure 35 for topology) has only been studied in the context of AD. Previous investigations 
revealed that decreased ABCC1 activity in ABCC1 knock-out AD mice lead to an increased Aβ 
accumulation compared to controls (Krohn et al., 2011). On the other hand, pharmacologically 
enhanced ABCC1 activity was found to reduce AD pathology by decreasing the Aβ burden in an 
AD mouse model (Krohn et al., 2011; Hofrichter et al., 2013). These results motivated the study 
of ABCC1 knock-out and activation on aSYN related pathology in the brain of tg-aSYN mice, in 
the present work.  
 
Figure 35: ABCC1 topology.  
The topology of ABCC1 is characterized by three membrane spanning domains (MSD) containing of ranging numbers 
but typically six transmembrane helices, and two nucleotide binding domains (NBD). The N-terminus is located 
extracellular, while the C-terminus lies intracellular (adapted from (Deeley et al., 2006)). 
Starting from the premise that ABCC1 excretes aSYN across the BBB in an ATP-dependent 
manner, a decreased ATP availability and thus, a diminished ABCC1 activity causes an increase 
of intracellular aSYN.  
According to the study of Krohn et al. (2011), mice at an age of 100 d were chosen. Histological 
analyzes revealed no differences upon ABCC1 knock-out. Surprisingly, the effect of ABCC1 
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knock-out on neuronal integrity and microglial immune response could be neglected. Even the 
level of monomeric, oligomeric and fibrillar aSYN in the brain of tg-aSYN and tg-aSYN-ABCC1-/- 
mice was not altered by ABCC1 knock-out at 100 d of age. The validation of an effect upon 
ABCC1 activation on the pathology was performed by pharmacologically activation using 
thiethylperazine (Torecan®, Novartis). Thiethylperazine, a derivate of phenothiazine belonging 
to the class of neuroleptics is widely used as antiemetic. Phenothiazines are known to interact 
with both, ABCB1 and ABCC1 differentially. While the drug enhances the activity of ABCC1 
vastly, as was shown in human erythrocyte culture, ABCB1 activity decreases upon treatment 
(Wesolowska et al., 2005; Wesolowska, 2011). 
In the present work, no difference was found between treated tg-aSYN and tg-aSYN-ABCC1-/- 
(control) mice with respect to neuronal integrity, microglial response and aSYN concentration. 
Thus, a missing transport of aSYN via ABCC1 can be concluded. Additonally, also a missing 
transport by ABCB1 can be stated as the decreased ABCB1 activity as well had no influence on 
any of these parameters. These findings are consistent with the report of Sui and coworkers who 
found that ABCB1 is not involved in the transport of aSYN and furthermore showed a bi-
directional transport of aSYN across the BBB via LRP-1 (Low density lipoprotein receptor-
related protein 1)(Sui et al., 2014).  
Possible reason for the differences between aSYN and Aβ concerning the transport across the 
BBB by ABC transporters are most likely the structural differences between the peptides. While 
Aβ has only an atomic mass of 4 kDa and forms β-sheet structure, aSYN is substantially heavier 
(14 kDa) and natively unfolded (Bartels et al., 2011). 
One very interesting effect observed in the present study was the increase of the neuronal area 
in water- and thiethylperazine-treated mice compared to untreated mice, which was 
independent of ABCC1 knock-out. It was furthermore detected that also the aSYN level in the 
carbonate-soluble fraction that includes monomeric and small oligomeric aSYN, increases upon 
treatment with thiethylperazine and water, respectively. This effect could possibly be triggered 
by stress and anxiety due to handling of the mice (Lapin, 1995) 
5.5 Conclusion 
Taken together, the results of the present work contribute to the understanding of 
mitochondrial deficiency in PD. Even if the tg-aSYN mice with the ‘A30P’ mutation display 
mainly extranigral aspects of PD and should rather be denoted as general model for 
synucleopathies, the expression of human aSYN in the brain was robust.  
The increased complex II activity due to the polymorphisms in the mtDNA of NOD/J mice was 
found to bypass the diminished respiration in the diseased mouse brain, leading to improved 
neuronal and behavioral physiology in the novel tg-aSYN-mtNOD mouse model. 
Discussion 
84 
 
A proposed increased ATP production causing an enhancement of various energy-dependent 
clearance mechanisms of the brain led to the follow-up study of an aSYN transport by the 
specific ABC transporter ABCC1. The hypothesized transport of aSYN by ABCC1, verified by a 
study determining the effect of a knock-out and the pharmacologically activation of ABCC1 on 
the pathology of tg-aSYN mice, was not confirmed. 
In sum, the work acknowledges beneficial and protective effects of specific mitochondrial 
polymorphisms in α-synucleinopathies that should be further investigated and utilized for 
future pharmaceutical applications. 
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